Cover
Cover - shares | 9 Months Ended | |
Jul. 31, 2022 | Sep. 06, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Jul. 31, 2022 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --10-31 | |
Entity File Number | 000-56323 | |
Entity Registrant Name | WESTERN MAGNESIUM CORPORATION | |
Entity Central Index Key | 0001801762 | |
Entity Tax Identification Number | 61-1934413 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 8180 Greensboro Drive | |
Entity Address, Address Line Two | Suite 720 | |
Entity Address, City or Town | McLean | |
Entity Address, State or Province | VA | |
Entity Address, Postal Zip Code | 22102 | |
City Area Code | (571) | |
Local Phone Number | 378-0762 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 450,265,776 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Jul. 31, 2022 | Oct. 31, 2021 |
Current assets | ||
Cash | $ 16,700 | $ 462,360 |
Other receivables | 94,696 | 151,485 |
Prepayments | 337,525 | 133,647 |
Deposits held by related parties | 349,338 | 486,462 |
Total Current assets | 798,259 | 1,233,954 |
Non-current assets | ||
Property, plant and equipment, net | 4,488,001 | 2,574,704 |
Right-of-use assets, net | 405,321 | 598,575 |
Mineral property costs | 93,453 | 93,453 |
Reclamation and other deposits | 12,729 | 12,826 |
TOTAL ASSETS | 5,797,763 | 4,513,512 |
Current liabilities | ||
Accounts payable and accrued liabilities | 3,434,539 | 1,989,316 |
Due to related parties | 1,520,834 | 1,026,817 |
Lease obligations – current | 259,936 | 192,045 |
Provision for flow through share issuances | 225,284 | 233,285 |
Convertible debenture, net | 1,942,838 | 7,449,807 |
Warrant liability | 57,080 | |
Total Current liabilities | 7,440,511 | 10,891,270 |
Non-current liabilities | ||
Lease obligations – non-current | 195,813 | 392,280 |
Total liabilities | 7,636,324 | 11,283,550 |
Commitments and contingencies [note 9] | ||
Shareholders’ deficit | ||
Capital stock Authorized: 1 billion common stock at par value of $0.001 Issued and paid: 449,265,776 (2021 – 392,943,398 | 41,811,321 | 29,842,167 |
Additional paid-in-capital | 23,188,545 | 15,186,480 |
Obligations to issue shares | 209,827 | |
Accumulated other comprehensive income | 352,345 | 121,109 |
Accumulated deficit | (67,190,772) | (52,129,621) |
Total shareholders’ deficit | (1,838,561) | (6,770,038) |
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | $ 5,797,763 | $ 4,513,512 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) | Jul. 31, 2022 $ / shares shares | Oct. 31, 2021 $ / shares shares |
Statement of Financial Position [Abstract] | ||
Common stock, shares authorized | 1,000,000,000 | 1,000,000,000 |
Common stock, par value | (per share) | $ 0.001 | $ 0.001 |
Common stock, shares issued | 449,265,776 | 392,943,398 |
Common stock, shares outstanding | 449,265,776 | 392,943,398 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jul. 31, 2022 | Jul. 31, 2021 | Jul. 31, 2022 | Jul. 31, 2021 | |
Operating expenses | ||||
Bank charges | $ 3,792 | $ 4,890 | $ 12,444 | $ 11,044 |
Business development | 66,883 | 144,212 | ||
Computer system and software | 23,766 | 11,854 | 63,120 | 83,639 |
Consulting and management fees | 181,193 | 274,094 | 594,829 | 613,048 |
Depreciation | 193,926 | 62,781 | 436,253 | 159,774 |
Due diligence expenses | 2,010 | 3,974 | ||
Engineering expenses | 101,617 | 17,295 | 218,425 | 72,749 |
Foreign exchange loss (gain) | 30,282 | (35,499) | 256,417 | (121,726) |
Interest and accretion | 372,295 | 28,242 | 1,021,443 | 64,576 |
Investor relations | 12,872 | 131,739 | 228,706 | 202,675 |
Legal and professional fees | 320,665 | 257,648 | 1,897,719 | 545,234 |
Office and general | 266,407 | 23,794 | 343,765 | 83,405 |
Property maintenance fees | 15,100 | 15,069 | 15,100 | 15,069 |
Rent and facilities | 119,625 | 68,635 | 295,746 | 153,910 |
Salaries and benefits | 1,151,045 | 809,253 | 3,347,884 | 2,176,185 |
Stock-based compensation | 32,539 | 1,057,013 | 466,368 | 1,057,013 |
Shareholder communications | 7,500 | (36,722) | 48,201 | 49,512 |
Subsidies and recoveries | 223 | (477) | (78,996) | (41,724) |
Transfer agent and regulatory fees | 95,618 | 37,508 | 184,355 | 61,138 |
Travel expenses | 137,548 | 107,546 | 359,491 | 218,222 |
Total operating expenses | 3,132,896 | 2,836,673 | 9,855,482 | 5,407,717 |
Other income (expense) | ||||
Change in fair value of derivative liability | (806,853) | 359,643 | (790,197) | |
Loss on recognition of debt host liability | (140,909) | (341,553) | (140,909) | |
Change in fair value of warrant liability | 1,837,031 | (5,223,759) | ||
Total other income (expense) | 1,837,031 | (947,762) | (5,205,669) | (931,106) |
Net loss | (1,295,865) | (3,784,435) | (15,061,151) | (6,338,823) |
Other comprehensive income (loss) | ||||
Foreign currency translation | 17,273 | 16,068 | 231,236 | (174,981) |
Comprehensive loss | $ (1,278,592) | $ (3,768,367) | $ (14,829,915) | $ (6,513,804) |
Basic and diluted loss per common share | $ 0 | $ (0.01) | $ (0.03) | $ (0.02) |
Weighted average number of common shares outstanding – basic and diluted | 444,004,303 | 365,235,017 | 494,284,490 | 340,461,383 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Shareholders' Deficit - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Obligation to Issue Shares [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Oct. 31, 2020 | $ 21,322,022 | $ 4,182,037 | $ 596,872 | $ 399,175 | $ (28,580,009) | $ (2,079,903) |
Beginning balance, shares at Oct. 31, 2020 | 323,419,527 | |||||
Shares issued pursuant to private placements [note 14[b]] | $ 5,754,705 | (596,872) | 5,157,833 | |||
Shares issued pursuant to private placements, shares | 53,151,881 | |||||
Shares issued on warrants exercised [notes 13 and 14[b]] | $ 33,131 | (4,291) | 28,840 | |||
Shares issued on warrants exercised, shares | 524,901 | |||||
Shares issued on options exercised [note 14[b]] | $ 36,150 | (23,879) | 12,271 | |||
Shares issued on options exercised, shares | 300,000 | |||||
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 14[b]] | $ 162,829 | 162,829 | ||||
Shares issued upon conversion of convertible debenture, shares | 1,360,959 | |||||
Shares issued for equipment [note 14[b]] | $ 305,832 | 305,832 | ||||
Shares issued for equipment, shares | 1,538,461 | |||||
Share issue costs [note 14[b]] | $ (573,289) | (573,289) | ||||
Stock-based compensation [note 14[d]] | 1,057,013 | 1,057,013 | ||||
Foreign currency translation | (174,981) | (174,981) | ||||
Net loss | (6,338,823) | (6,338,823) | ||||
Ending balance, value at Jul. 31, 2021 | $ 27,041,380 | 5,210,880 | 224,194 | (34,918,832) | (2,442,378) | |
Ending balance, shares at Jul. 31, 2021 | 380,295,729 | |||||
Beginning balance, value at Oct. 31, 2021 | $ 29,842,167 | 15,186,480 | 209,827 | 121,109 | (52,129,621) | (6,770,038) |
Beginning balance, shares at Oct. 31, 2021 | 392,943,398 | |||||
Shares issued pursuant to private placements [note 14[b]] | $ 1,373,274 | (598,528) | 774,746 | |||
Shares issued pursuant to private placements, shares | 3,842,499 | |||||
Shares issued on warrants exercised [notes 13 and 14[b]] | $ 9,604,902 | 9,604,902 | ||||
Shares issued on warrants exercised, shares | 32,633,121 | |||||
Shares issued on options exercised [note 14[b]] | $ 162,443 | (70,263) | 92,180 | |||
Shares issued on options exercised, shares | 1,750,000 | |||||
Shares issued upon conversion of convertible debenture [notes 12[b], 12[c] and 14[b]] | $ 888,178 | 888,178 | ||||
Shares issued upon conversion of convertible debenture, shares | 8,933,333 | |||||
Share issue costs [note 14[b]] | $ (59,643) | (59,643) | ||||
Stock-based compensation [note 14[d]] | 466,368 | 466,368 | ||||
Foreign currency translation | 231,236 | 231,236 | ||||
Net loss | (15,061,151) | (15,061,151) | ||||
Shares issued for finder’s fees [notes 8[d][v] and 14[b]] | ||||||
Shares issued for finder's fees, shares | 9,163,425 | |||||
Beneficial conversion feature on convertible debentures [note 12[d]] | 240,000 | 240,000 | ||||
Effects of change in functional currency on convertible debentures [note 12[e]] | 7,370,158 | 7,370,158 | ||||
Effects of change in functional currency on broker warrants [note 13] | (4,198) | (4,198) | ||||
Share subscriptions [note 14[f]] | 388,701 | 388,701 | ||||
Ending balance, value at Jul. 31, 2022 | $ 41,811,321 | $ 23,188,545 | $ 352,345 | $ (67,190,772) | $ (1,838,561) | |
Ending balance, shares at Jul. 31, 2022 | 449,265,776 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Jul. 31, 2022 | Jul. 31, 2021 | Jul. 31, 2022 | Jul. 31, 2021 | Oct. 31, 2021 | |
OPERATING ACTIVITIES | |||||
Net loss | $ (1,295,865) | $ (3,784,435) | $ (15,061,151) | $ (6,338,823) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Change in fair value of derivative liability | 806,853 | (359,643) | 790,197 | ||
Loss on recognition of debt host liability | 140,909 | 341,553 | 140,909 | ||
Change in fair value of warrant liability | (1,837,031) | 5,223,759 | |||
Cashless warrant exercise | (113,765) | ||||
Accrued interest and accretion | 196,115 | 32,124 | |||
Amortization of debt discount | 814,729 | ||||
Depreciation of property, plant and equipment | 258,515 | 22,355 | |||
Depreciation of right-of-use assets | 177,738 | 137,419 | |||
Foreign exchange loss (gain) | 23,535 | (27,812) | |||
Interest expense on lease obligations | 25,905 | 16,946 | |||
Shares issued for equipment | 165,659 | ||||
Stock-based compensation | 32,539 | 1,057,013 | 466,368 | 1,057,013 | |
Changes in operating assets and liabilities: | |||||
Other receivables | 51,963 | (118,276) | |||
Prepayments | (209,967) | (32,436) | |||
Deposits held by related parties | 121,301 | (653,915) | |||
Accounts payable and accrued liabilities | 1,524,962 | 877,574 | |||
Due to related parties | 532,489 | (85,623) | |||
Cash used in operating activities | (5,985,595) | (4,016,689) | |||
INVESTING ACTIVITIES | |||||
Purchase of property, plant and equipment | (2,252,600) | (1,779,316) | |||
Cash used in investing activities | (2,252,600) | (1,779,316) | |||
FINANCING ACTIVITIES | |||||
Proceeds from issuance of shares, net of share issuance costs | 5,943,775 | 4,773,200 | |||
Proceeds from convertible debenture | 2,000,000 | 1,579,475 | |||
Payments of promissory note | (65,745) | ||||
Payments of lease obligations | (143,672) | (153,145) | |||
Cash provided by financing activities | 7,800,103 | 6,133,785 | |||
Change in cash for the period | (438,092) | 337,780 | |||
Cash, beginning of the period | 462,360 | 39,571 | $ 39,571 | ||
Effect of foreign exchange on cash | (7,568) | 5,892 | |||
Cash, end of the period | $ 16,700 | $ 383,243 | 16,700 | 383,243 | $ 462,360 |
Other non-cash transactions: | |||||
Shares issued for conversion of debt and interest | 888,178 | ||||
Shares issued for payment of finder’s fees | 4,796,832 | ||||
Other cash flow disclosures: | |||||
Cash paid during the period for interest | $ 10,581 |
NATURE OF OPERATIONS AND GOING
NATURE OF OPERATIONS AND GOING CONCERN | 9 Months Ended |
Jul. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NATURE OF OPERATIONS AND GOING CONCERN | 1. NATURE OF OPERATIONS AND GOING CONCERN Western Magnesium Corporation (the “Company”, or “WMC”) was incorporated under the laws of British Columbia on March 24, 1966. On May 14, 2019, the Company discontinued from the jurisdiction of the Business Corporations Act (British Columbia) and domesticated under the General Corporation Law of the State of Delaware under the name “Western Magnesium Corporation”. The Company is a reporting issuer in Canada and in the United States, listed for trading in Canada on the TSX Venture Exchange (the “TSX-V”) under the symbol “WMG.V”, in the United States on the OTCQB tier of the OTC Markets (the “OTCQB”) under the symbol “MLYF”, and in Germany on the Frankfurt Stock Exchange under the symbol “3WM”. The Company has developed proprietary magnesium production technology with the aim of becoming a premier low-cost producer of green primary magnesium metal. As at July 31, 2022, the Company had an accumulated deficit of $ 67,190,772 52,129,621 6,642,252 9,657,316 14,829,915 6,513,804 These unaudited condensed consolidated financial statements (the “Financial Statements”) have been prepared under the assumption that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will be able to meet its obligations and continue its operations for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. If future financing through share or debt issuances is unavailable or if for any reason the Company is unable to continue as a going concern, it could impact the Company’s ability to realize its assets at their recognized values and to meet its obligations in the ordinary course of business at the amounts stated in these Financial Statements. These Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern. If the going concern assumption is not used, the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these Financial Statements. The Company’s management has evaluated whether there is substantial doubt about the Company’s ability to continue as a going concern and has determined that substantial doubt existed as of July 31, 2022. This determination was based on the following factors: (i) the Company used cash of approximately $ 6 In March 2020, the World Health Organization declared COVID-19 a global pandemic. In order to combat the spread of COVID-19, governments worldwide, including the Unites States and Canada, have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures. These measures have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company has not been significant but could affect the Company’s ability to raise financings in the future and restrict travel. Management continues to monitor the situation. |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 9 Months Ended |
Jul. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
BASIS OF PRESENTATION | 2. BASIS OF PRESENTATION These Financial Statements comprise the financial statements of Western Magnesium Corporation and its wholly owned subsidiaries, Western Magnesium Corp., incorporated in Nevada, United States and Western Magnesium Canada Corporation, incorporated in British Columbia, Canada. [a] Accounting standards The accompanying Financial Statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) on the basis that the Company will continue as a going concern, which assumes that the Company will be able to meet its obligations as they become due and continue its operations for at least one year from the date these Financial Statements are issued. Realization values may be substantially different from carrying values as shown and these Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. These Financial Statements have been prepared on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these Financial Statements have been prepared using the accrual basis of accounting, except for cash flow information. They do not include all the information required for complete annual financial statements and should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended October 31, 2021 (the “Fiscal 2021 Financial Statements”). [b] Functional and presentation currency These Financial Statements are presented in United States dollars (“US dollars” or “US$”), except where otherwise indicated. The functional currency of each entity of the Company is as follows: Entity Functional Currency Western Magnesium Corporation United States dollars Western Magnesium Corp. United States dollars Western Magnesium Canada Corporation Canadian dollars (“CA$”) During the three months ended January 31, 2022, significant changes in economic facts and circumstances have occurred in Western Magnesium Corporation’s operations which resulted in the change of its functional currency to the United States dollar from the Canadian dollar effective November 1, 2021. For both monetary and non-monetary assets and liabilities, translated balances at the end of the prior period became the new accounting basis. The rate on the date of change became the historical rate at which non-monetary assets and liabilities were translated in subsequent years. There was no effect on the cumulative translation adjustment on the consolidated basis. Previously recorded cumulative translation adjustments were not reversed. Effects of change in functional currency included the reclassifications of convertible debentures and warrants and broker warrants [notes 12[d] and [e]] The accounts of the Company’s subsidiary Western Magnesium Canada Corporation have been translated to United States dollars with the exchange translation adjustments recorded in other comprehensive income (loss). [c] Critical accounting estimates and judgments The preparation of these Financial Statements in accordance with US GAAP requires the Company to make estimates and assumptions concerning the future that affect the amounts reported in the Financial Statements and accompanying notes. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Estimates and assumptions where there is potential risk of material adjustments to assets and liabilities in future accounting periods include the useful lives of property, plant and equipment, recoverability of the carrying value of exploration and evaluation assets, fair value measurements for financial instruments, discount rates for leases, recoverability and measurement of deferred tax assets and liabilities, and contingent liabilities. Significant Judgments The preparation of these Financial Statements in accordance with US GAAP requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s Financial Statements include: - the assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to substantial doubt; - whether there are indicators of impairment of the Company’s exploration and evaluation assets and other non-current assets; - the classification of financial instruments; and - determination of functional currency. |
RECENT ACCOUNTING PRONOUNCEMENT
RECENT ACCOUNTING PRONOUNCEMENTS | 9 Months Ended |
Jul. 31, 2022 | |
Accounting Changes and Error Corrections [Abstract] | |
RECENT ACCOUNTING PRONOUNCEMENTS | 3. RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Standards Adopted During the Periods In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements. In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments – Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interactions of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, with early adoption permitted. Effective November 1, 2021, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements. New Accounting Standards Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments and supersedes the respective guidance within ASC 470-20 and ASC 740-10-55-51, which will result in more instruments to be accounted for as a single instrument rather than having their proceeds allocated between liability and equity accounting units. As smaller reporting companies as defined by the United States Securities and Exchange Commission (the “SEC”), ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Financial Statements. |
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT | 9 Months Ended |
Jul. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY, PLANT AND EQUIPMENT | 4. PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Computer Equipment Furniture Leasehold Improvement Furnace & Plant Equipment Vehicle Total $ $ $ $ $ $ Cost Balance, October 31, 2021 109,629 53,542 139,481 2,344,726 – 2,647,378 Property, plant and equipment cost, beginning balance 109,629 53,542 139,481 2,344,726 – 2,647,378 Additions 14,370 2,171 159,065 2,047,779 29,215 2,252,600 Foreign exchange effect 10 (314 ) (5,708 ) (76,255 ) (374 ) (82,641 ) Balance, July 31, 2022 124,009 55,399 292,838 4,316,250 28,841 4,817,337 Property, plant and equipment cost, ending balance 124,009 55,399 292,838 4,316,250 28,841 4,817,337 Accumulated Depreciation Balance, October 31, 2021 27,821 16,514 14,147 14,192 – 72,674 Property, plant and equipment accumulated depreciation, beginning balance 27,821 16,514 14,147 14,192 – 72,674 Depreciation expense 28,402 5,777 81,553 137,294 5,084 258,515 Foreign exchange effect 403 (52 ) (856 ) (906 ) (37 ) (1,853 ) Balance, July 31, 2022 56,626 22,239 94,844 150,580 5,047 329,336 Property, plant and equipment accumulated depreciation, ending balance 56,626 22,239 94,844 150,580 5,047 329,336 Net Book Value Balance, October 31, 2021 81,808 37,028 125,334 2,330,534 – 2,574,704 Balance, July 31, 2022 67,383 33,160 197,994 4,165,670 23,794 4,488,001 |
RIGHT-OF-USE ASSETS
RIGHT-OF-USE ASSETS | 9 Months Ended |
Jul. 31, 2022 | |
Right-of-use Assets | |
RIGHT-OF-USE ASSETS | 5. RIGHT-OF-USE ASSETS As at July 31, 2022, the right-of-use assets were leases for the Company’s offices in Vancouver, British Columbia and McLean, Virginia, and its research and development pilot plant located in Burnaby, British Columbia. These leases terminate on March 31, 2023, February 28, 2025 and September 30, 2023, respectively. The lease for the Company’s office in Las Vegas, Nevada ended on May 31, 2021. SCHEDULE OF RIGHT-OF-USE ASSETS Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Cost Balance, October 31, 2021 156,881 292,391 24,580 384,946 858,798 Beginning balance, Cost 156,881 292,391 24,580 384,946 858,798 Foreign exchange effect – (3,038 ) – (13,208 ) (16,246 ) Balance, July 31, 2022 156,881 289,353 24,580 371,738 842,552 Ending balance, Cost 156,881 289,353 24,580 371,738 842,552 Accumulated Depreciation Balance, October 31, 2021 90,277 15,529 24,580 129,837 260,223 Beginning balance, Accumulated Depreciation 90,277 15,529 24,580 129,837 260,223 Depreciation expense 33,456 50,562 – 93,720 177,738 Prepaid expense – 4,557 – – 4,557 Foreign exchange effect – (162 ) – (5,125 ) (5,287 ) Balance, July 31, 2022 123,733 70,486 24,580 218,432 437,231 Ending balance, Accumulated Depreciation 123,733 70,486 24,580 218,432 437,231 Net Book Value Balance, October 31, 2021 66,604 276,862 – 255,109 598,575 Balance, July 31, 2022 33,148 218,867 – 153,306 405,321 |
LEASE OBLIGATIONS
LEASE OBLIGATIONS | 9 Months Ended |
Jul. 31, 2022 | |
Lease Obligations | |
LEASE OBLIGATIONS | 6. LEASE OBLIGATIONS On adoption of ASU 2016-02 on November 1, 2019, the Company recognized lease liabilities of $ 83,549 7% During the year ended October 31, 2020, the Company entered into a new operating lease with respect to its research and development pilot plant located in Burnaby, British Columbia and recognized a lease liability of $ 354,263 6% During the year ended October 31, 2021, the Company renewed its operating lease with respect to its office in Vancouver, British Columbia and recognized a lease liability of $ 91,237 7% During the year ended October 31, 2021, the Company entered into a new operating lease with respect to its corporate head office in McLean, Virginia and recognized a lease liability of $ 260,649 7% SCHEDULE OF OPERATING LEASE Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 Lease obligation, beginning 66,604 262,612 – 255,109 584,325 Lease payments (36,087 ) (4,557 ) – (103,028 ) (143,672 ) Interest expense 2,631 13,967 – 9,307 25,905 Foreign exchange effect – (2,728 ) – (8,081 ) (10,089 ) Balance, July 31, 2022 33,148 269,294 – 153,307 455,749 Lease obligation, ending 33,148 269,294 – 153,307 455,749 Which consist of: Current lease obligation 33,148 96,043 – 130,745 259,936 Non-current lease obligation – 173,251 – 22,562 195,813 Balance, July 31, 2022 33,148 269,294 – 153,307 455,749 Lease obligation, ending 33,148 269,294 – 153,307 455,749 |
MINERAL PROPERTY COSTS
MINERAL PROPERTY COSTS | 9 Months Ended |
Jul. 31, 2022 | |
Extractive Industries [Abstract] | |
MINERAL PROPERTY COSTS | 7. MINERAL PROPERTY COSTS As at July 31, 2022, the Company had the following mining claims: [a] Silverado Property Nevada, United States The Silverado property is located in the Pinto mining district of Nevada, consists of 3 patented mining claims totaling approximately 120 100% 1 [b] Tami Mosi Property, Nevada, United States The Company holds a 100% 1,637 10 2% 93,452 |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Jul. 31, 2022 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | 8. RELATED PARTY TRANSACTIONS [a] Deposits held by related parties Pursuant to vendor agreements entered on January 1, 2021, the Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses (the “Pilot Plant Advances”). As at July 31, 2022, the Company had the following deposits held by related parties: SCHEDULE OF DEPOSITS HELD BY RELATED PARTY Related Party A [i] Related Party B [ii] Total $ $ $ Balance, October 31, 2021 291,481 194,981 486,462 Beginning balance 291,481 194,981 486,462 Advances 354,459 1,225,118 1,579,577 Costs and expenses (312,820 ) (1,420,829 ) (1,733,649 ) Foreign exchange effect 16,218 730 16,948 Balance, July 31, 2022 349,338 – 349,338 Ending balance 349,338 – 349,338 [i] Related Party A is a company controlled by a director and officer. [ii] Related Party B is a company controlled by an officer. [b] Due to related parties As at July 31, 2022, balances due to related parties totaled $ 1,520,834 1,026,817 SCHEDULE OF DUE TO RELATED PARTIES July 31, 2022 October 31, 2021 $ $ Wages payable to directors and officers 505,544 357,500 Benefits payable to directors and officers 725,261 539,209 Fees and expenses payable to directors and officers 290,029 127,878 Interest due to a shareholder – 2,230 Total 1,520,834 1,026,817 [c] Key management compensation As at July 31, 2022, the Company had eleven executives including nine senior management members. Their aggregate annualized compensation is approximately $ 3.3 2,605,352 160,700 [d] Transactions with related parties [i] During the nine months ended July 31, 2022, the Company incurred consulting fees of $ 27,489 35,000 [ii] During the nine months ended July 31, 2022, the Company incurred consulting fees of $ 60,000 [iii] During the nine months ended July 31, 2022, the Company incurred consulting fees of $ 29,600 [iv] In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 7,656 9,794 [v] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5% 5 9,163,425 0.65 4,796,832 5,956,226 |
CONTINGENT LIABILITIES AND COMM
CONTINGENT LIABILITIES AND COMMITMENTS | 9 Months Ended |
Jul. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
CONTINGENT LIABILITIES AND COMMITMENTS | 9. CONTINGENT LIABILITIES AND COMMITMENTS [a] Contingent liabilities [i] On September 29, 2020, James Sever filed a Notice of Civil Claim against the Company in the Supreme Court of British Columbia (the “Sever Claim”). The Sever Claim alleges that Mr. Sever had an employment and/or other similar contractual relationship with the Company, and that the Company breached such contractual relationship by way of constructive dismissal or similar conduct. The Sever Claim seeks damages in excess of $ 2.5 [ii] On December 31, 2020, GEM Yield Bahamas Limited (“GEM”) served the Company with a Notice of Intention to Arbitrate (the “New York Arbitration Notice”) before the American Arbitration Association in New York (the “GEM New York Arbitration”). The New York Arbitration Notice alleges the Company breached a Share Subscription Agreement dated November 15, 2019 entered into between the Company and GEM (the “GEM Agreement”), among other things, claiming damages of approximately $ 3.4 4.2 [iii] On February 8, 2021, GEM instituted another arbitration against the Company before the International Centre for Dispute Resolution in Montreal Canada (the “GEM Montreal Arbitration”) and joined GEM’s affiliate, GEM Global Yield LLC SCS (“GEM Global Yield” together with GEM, the “GEM Parties”). The Statement of Claim filed by the GEM Parties alleges the Company breached a Share Subscription Agreement dated November 15, 2019 and promissory note, among other things, claiming damages of approximately $ 3.9 4.9 33 [iv] On April 19, 2021, Lampert Advisors, LLC (“Lampert”) filed a Verified Complaint against the Company’s wholly owned subsidiary Western Magnesium Corp., a Nevada corporation (“Western Magnesium – Nevada”) in the Supreme Court of the State of New York, County of New York (the “Lampert Lawsuit”). The complaint filed in the Lampert Lawsuit alleges that Lampert entered into an agreement with Western Magnesium – Nevada to provide various financial advisory services including acquisition advisory services and act as an exclusive placement agent for a combination of debt and equity securities (the “Lampert Agreement”), that it performed all services required under that agreement and that it is owed $ 367,227 9% 120,000 [b] Commitments [i] On November 1, 2016, the Company signed a contract services agreement with Lodestar Management Group, LLC (“Lodestar”), a US corporate logistics company. Lodestar provides advisory, consulting, negotiation and other management services relating to corporate management, administrative and/or operational activities of the Company. The term of the contract was for one year and has been renewed under the same terms on January 1, 2018 and 2019. The Company has agreed to compensate Lodestar in the amount of $ 1,800 2,500 0.05 1,800 2,500 no nil 30,624 16,200 634,072 38,593 53,491 [ii] During the year ended October 31, 2020, the Company entered into a lease agreement for its research and development pilot plant in Burnaby, British Columbia with a lease term from October 1, 2020 to September 30, 2023 16,154 20,715 lease term from April 1, 2021 to March 31, 2023 7,637 9,794 lease term from September 14, 2021 to February 28, 2025 9,113 41,010 [notes 5 and 6] |
PROMISSORY NOTE
PROMISSORY NOTE | 9 Months Ended |
Jul. 31, 2022 | |
Promissory Note | |
PROMISSORY NOTE | 10. PROMISSORY NOTE During the year ended October 31, 2019, the Company received a loan of $ 112,895 150,000 18% 44,588 60,000 157,483 210,000 September 24, 2021 1,639 16,655 65,761 101,066 |
PROVISION FOR FLOW THROUGH SHAR
PROVISION FOR FLOW THROUGH SHARE ISSUANCES | 9 Months Ended |
Jul. 31, 2022 | |
Provision For Flow Through Share Issuances | |
PROVISION FOR FLOW THROUGH SHARE ISSUANCES | 11. PROVISION FOR FLOW THROUGH SHARE ISSUANCES The Company has recorded a provision in the amount of $ 225,284 233,285 |
CONVERTIBLE DEBENTURE
CONVERTIBLE DEBENTURE | 9 Months Ended |
Jul. 31, 2022 | |
Debt Disclosure [Abstract] | |
CONVERTIBLE DEBENTURE | 12. CONVERTIBLE DEBENTURE [a] July 2020 Convertible Debenture On July 27, 2020, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 112,124 150,000 12% 0.15 1,360,959 263,973 26,286 37% [b] July 2021 Convertible Debenture On July 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 79,542 100,000 12% 0.12 0.20 933,333 594 [c] June 2021 Convertible Debenture On June 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 1,500,000 12% December 10, 2022 15,000,000 each unit consists of (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion As part of the offering of the June 2021 Convertible Debenture, the Company also entered into a securities purchase agreement dated June 10, 2021 (the “2021 Securities Purchase Agreement”), whereby the Company agreed to use commercially reasonable efforts to file a registration statement with the United States Securities and Exchange Commission (the “SEC”) by August 14, 2021, covering the public resale of the shares of common stock underlying such debenture and, upon its conversion, the Class A and B Warrants issuable upon such conversion (the “Underlying Shares”), and to use its best efforts to cause the registration statement to be declared effective on October 13, 2021. On December 13, 2021, the Company’s Form 10 Registration Statement filed with the SEC was declared effective. In addition to certain covenants contained in the 2021 Securities Purchase Agreement, the terms of the June 2021 Convertible Debenture contain certain negative covenants by the Company, including, among others, sell or offer to sell any securities with non-fixed or floating price features, issue any common stock or common stock equivalents at a price lower than the conversion price herein then in effect, or issue any equity or debt instruments with anti-dilution provisions. In the event the Company issues or sells any common stock or common stock equivalents with terms that the purchaser holding the outstanding June 2021 Convertible Debenture or the Class A and B Warrants reasonably believes are more favorable to such holder than the terms of the June 2021 Convertible Debenture or the Class A and B Warrants, then upon notice to the Company by such holder within five trading days after notice to such holder by the Company, the Company will use commercially reasonable efforts to obtain the approval of the TSX-V and any additional required regulatory approval to amend the terms of the June 2021 Convertible Debenture or the Class A and B Warrants as required, as the case may be, so as to give such holder the benefit of such more favorable terms or conditions. The conversion price of the June 2021 Convertible Debenture and the exercise price of the Class A and B Warrants are subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events, including merger or consolidation of the Company or in a “Fundamental Transaction” as defined in the June 2021 Convertible Debenture. The Company has granted the holders certain rights of first refusal on its future offerings for as long as the June 2021 Convertible Debenture or the Class A and B Warrants are outstanding. The Company may prepay and satisfy the June 2021 Convertible Debenture so long as an event of default has not occurred, upon 20 days’ prior written notice received by the Company to the holder, by paying 125% of the amounts owed on the June 2021 Convertible Debenture, including all principal, interest and other fees. The holder of this debenture may, however, convert all or a portion of the debenture during the 20-day notice period. During the nine months ended July 31, 2022, the Company issued an aggregate 8,000,000 8,000,000 4,000,000 0.13 4,000,000 0.19 [note 13[b]] 165,140 70,521 effective interest rate of 1,113% [d] April 2022 Convertible Debenture On April 14, 2022, the Company entered into a securities purchase agreement (the “2022 Securities Purchase Agreement”) and closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 2,000,000 15% October 14, 2023 6,666,667 0.40 five years The April 2022 Convertible Debenture may not be prepaid prior to maturity and contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the 2022 Securities Purchase Agreement or the April 2022 Convertible Debenture. In the event of default under the April 2022 Convertible Debenture, the interest rate shall increase to the lesser of 20% per annum or the maximum rate permitted under applicable law until paid and the following “Mandatory Default Amount” shall be paid, if demanded by the purchaser: the sum of (a) the greater of (i) the outstanding principal amount of the April 2022 Convertible Debenture divided by the conversion price on the date the Mandatory Default Amount is either (A) demanded (if demand or notice is required to create an event of default) or otherwise due or (B) paid in full, whichever has a lower conversion price, multiplied by the VWAP on the date the Mandatory Default Amount is either (x) demanded, (y) due, or (z) paid in full, whichever is highest, or (ii) 125% of the outstanding principal amount of the April 2022 Convertible Debenture plus (b) all other amounts, costs, expenses and liquidated damages due in respect of the April 2022 Convertible Debenture. Pursuant to the terms of the 2022 Securities Purchase Agreement, the Company also entered into a registration rights agreement dated April 14, 2022 (the “2022 Registration Rights Agreement”). Pursuant to the terms of the 2022 Registration Rights Agreement, the Company agreed to prepare and file with the SEC a registration statement covering the resale of all shares issued or issuable upon conversion of the April 2022 Convertible Debenture, upon exercise of the respective warrants of the April 2022 Convertible Debenture, upon conversion of the June 2021 Convertible Debenture, and upon exercise of the respective warrants of the June 2021 Convertible Debenture. The Company agreed to file the registration statement with the SEC within 30 days following April 14, 2022 and to use best efforts to have the registration statement declared effective by the SEC within 60 days following April 14, 2022 if the SEC does not review it or by August 12, 2022 if the SEC reviews it. In the event the Company fails to file the registration statement or such registration statement is not declared effective within the time periods noted above or such registration statement is not kept effective while any of the securities registered pursuant to such registration statement, the Company will be obligated to pay the holder of the debentures a penalty in cash, in the amount of $ 20,000 As at July 31, 2022, the Company incurred contractual interest of $ 88,767 nil 22% [e] Debt Host Liability and Embedded Derivative Liability Certain of the Company’s convertible debentures were determined to be hybrid financial instruments comprised of a debt host liability and an embedded derivative liability, as under the conversion feature the number of shares that will or may be issued to settle the notes may vary. The Company uses the Black-Scholes Option Pricing Model based on different default risks and assumptions. The debt host liability of the convertible note will be measured at amortized cost, with the embedded derivative liability measured at fair value. On issuance date of the July 2020 Convertible Debenture, the fair value of its debt host liability was determined to be $ 87,083 25,041 On issuance date of the July 2021 Convertible Debenture, it was determined to be a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The Company allocated the intrinsic value of the beneficial conversion feature of the July 2021 Convertible Debenture capped at the face value of $ 79,542 100,000 421,095 529,400 341,553 429,400 On issuance date of the June 2021 Convertible Debenture, it was determined to be a hybrid financial instrument comprised of a debt host liability and an embedded derivative liability. The embedded derivative liability was valued at $ 1,646,600 1,500,000 1 146,601 7,449,744 814,717 685,283 On issuance date of the April 2022 Convertible Debenture, it was determined to be a convertible debt instrument with a beneficial conversion feature accounted for in accordance with ASU 470-20. The Company allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture of $ 240,000 12 239,988 SCHEDULE OF DERIVATIVE INSTRUMENTS July 2020 Convertible Debenture July 2021 Convertible Debenture June 2021 Convertible Debenture April 2022 Convertible Debenture Total $ $ $ $ $ Debt Host Liability Balance, October 31, 2020 96,318 – – – 96,318 Fair value of debt host liability recognized – – 1 – 1 Accretion and interest expense 23,587 63 43 – 23,693 Conversion (125,560 ) – – – (125,560 ) Foreign currency translation 5,655 – – – 5,655 Balance, October 31, 2021 – 63 44 – 107 Effects of functional currency change – – 1,500,000 – 1,500,000 Fair value at inception – – – 2,000,000 2,000,000 Accretion and interest expense – 28,050 49,406 118,659 196,115 Conversion – (28,031 ) (800,000 ) – (828,031 ) Foreign currency translation – (82 ) – – (82 ) Balance, July 31, 2022 – – 749,450 2,118,659 2,868,109 Embedded Derivative Liability Balance, October 31, 2020 20,123 – – – 20,123 Fair value of embedded derivative liability recognized – – 1,646,600 – 1,646,600 Fair value adjustment (16,058 ) – 5,717,328 – 5,701,270 Conversion (5,247 ) – – – (5,247 ) Foreign currency translation 1,182 – 85,772 – 86,954 Balance, October 31, 2021 – – 7,449,700 – 7,449,700 Effects of functional currency change – 421,094 (7,449,700 ) – (7,028,606 ) Fair value adjustment – (259,447 ) – – (259,447 ) Conversion – (158,169 ) – – (158,169 ) Foreign currency translation – (3,478 ) – – (3,478 ) Balance, July 31, 2022 – – – – – Debt Discount Balance, October 31, 2021 – – – – – Effects of functional currency change – – (1,500,000 ) – (1,500,000 ) Fair value at inception – – – (240,000 ) (240,000 ) Amortization – – 814,717 12 814,729 Balance, July 31, 2022 – – (685,283 ) (239,988 ) (925,271 ) Combined Value of Convertible Debenture Balance, October 31, 2020 116,441 – – – 116,441 Balance, October 31, 2021 – 63 7,449,744 7,449,744 7,449,807 Balance, July 31, 2022 – – 64,167 1,878,671 1,942,838 The inputs used in the Black-Scholes Option Pricing Model are as follows: SCHEDULE OF OPTION PRICING MODEL April 22, November 1, October 31, June 15, July 27, 2022 2021 2021 2021 2020 Risk free rate of interest 2.65% 1.07% 1.08% 0.31% 0.26% Expected life in years 0.23 0.70 1.11 1.50 0.74 Conversion exercise price CA$ 0.12 CA$ 0.12 $ 0.10 $ 0.10 CA$ 0.15 Underlying share price of the Company CA$ 0.36 CA$ 0.75 $ 0.59 $ 0.19 CA$ 0.13 Expected volatility 99.90% 124.34% 107.62% 87.17% 82.54% Expected dividend rate Nil Nil Nil Nil Nil |
WARRANT LIABILITY
WARRANT LIABILITY | 9 Months Ended |
Jul. 31, 2022 | |
Warrant Liability | |
WARRANT LIABILITY | 13. WARRANT LIABILITY On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value. The previous value of outstanding broker warrants of $ 4,198 26,956,177 76,811 67,155 5,057,112 21,985,951 57,080 nil SCHEDULE OF WARRANTS LIABILITY Warrants Broker Warrants Total $ $ $ Warrant Liability Balance, October 31, 2021 – – – Effects of functional currency change 26,956,177 76,811 27,032,988 Fair value at inception 67,155 – 67,155 Exercised (5,036,522 ) (20,590 ) (5,057,112 ) Fair value adjustment (21,929,730 ) (56,221 ) (21,985,951 ) Balance, July 31, 2022 57,080 – 57,080 Change in Fair Value of Warrant Liability Effects of functional currency change (26,956,177 ) (76,811 ) (27,032,988 ) Additional paid-in capital adjustment – 4,198 4,198 Fair value at inception (67,155 ) – (67,155 ) Cashless warrant exercised (113,765 ) – (113,765 ) Fair value adjustment 21,929,730 56,221 21,985,951 Total (5,207,367 ) (16,392 ) (5,223,759 ) |
SHARE CAPITAL
SHARE CAPITAL | 9 Months Ended |
Jul. 31, 2022 | |
Equity [Abstract] | |
SHARE CAPITAL | 14. SHARE CAPITAL [a] Authorized capital The authorized share capital consists of 1,000,000,000 0.001 [b] Common shares issued Fiscal 2021 [i] In connection with the non-brokered private placement announced on September 10, 2020: On November 20, 2020, the Company closed the first tranche of the non-brokered private placement, issuing 5,599,171 0.13 556,876 727,892 On January 15, 2021, the Company closed the second tranche of the non-brokered private placement, consisting of 7,337,914 0.13 749,435 953,930 39,996 On January 29, 2021, the Company closed the third tranche of the non-brokered private placement consisting of 5,382,303 0.13 547,496 699,699 On March 24, 2021, the Company closed the fourth tranche of the non-brokered private placement consisting of 6,554,172 0.13 678,270 852,042 On April 27, 2021, the Company closed the fifth and final tranche of the non-brokered private placement consisting of 851,395 0.13 89,237 110,681 In total, the Company issued an aggregate 25,724,955 0.13 2,621,314 3,344,244 Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche 195,614 [ii] On May 5, 2021, the Company announced a non-brokered private placement priced at CA$ 0.13 3,000,000 5,223,420 0.13 561,844 679,044 17,853,506 0.13 1,880,687 2,320,956 23,076,926 0.13 2,442,531 3,000,000 Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche 154,336 [iii] On May 18, 2021, the Company issued a total of 1,360,959 263,973 26,286 [iv] On June 7, 2021, the Company issued 1,538,461 0.24 305,832 369,231 [v] On July 16, 2021, the Company closed a non-brokered private placement and issued 4,350,000 0.20 690,860 870,000 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing 48,319 [vi] On August 11, 2021, the Company closed a non-brokered private placement and issued 3,827,601 0.55 1,683,336 2,105,180 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 for a period of eighteen months from the date of closing 124,923 8,444 [vii] During the year ended October 31, 2021, the Company issued a total of 7,014,969 0.05 0.21 887,520 1,120,130 525,173 [viii] During the year ended October 31, 2021, the Company issued a total of 2,630,000 0.05 0.16 140,734 175,800 [ix] With respect to the exercises of common share purchase warrants and options, the Company reclassified $ 4,291 121,932 Fiscal 2022 [i] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer was eligible to receive up to 5 5 9,163,425 0.65 4,796,832 5,956,226 [ii] On November 4, 2021, the Company issued 1,000,000 1,000,000 500,000 500,000 1,000,000 1,000,000 500,000 500,000 1,000,000 1,000,000 500,000 500,000 0.13 0.19 1,361 [iii] On November 26, 2021, the Company closed a non-brokered private placement and issued 1,375,499 0.55 756,524 0.75 26,656 [iv] During the three months ended January 31, 2022, upon exercise of common share purchase warrants, the Company issued an aggregate 15,159,448 0.19 2,279,136 2,880,295 200,000 0.05 7,830 10,000 30,000 0.30 6,981 9,000 15,389,448 2,293,946 2,899,295 2,428,363 [v] On March 10, 2022, the Company issued 1,000,000 1,000,000 500,000 500,000 2,000,000 2,000,000 1,000,000 1,000,000 0.13 0.19 [vi] On April 22, 2022, the Company issued a total of 933,333 933,333 0.20 100,000 12,000 [vii] During the three months ended April 30, 2022, upon the exercise of common share purchase warrants, the Company issued an aggregate 929,005 0.19 929,005 1,177,755 2,082,025 0.05 81,354 104,101 30,960 0.30 7,357 9,288 3,191,933 40,000 [viii] During the three months ended April 30, 2022, the Company issued a total of 750,000 0.05 29,715 37,500 22,203 [ix] On April 18, 2022, the Company announced a non-brokered private placement priced at $ 0.25 3,000,000 1,727,000 0.25 431,750 740,000 0.25 185,000 2,467,000 616,750 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing of the respective financing tranche 23,182 [x] On June 8, 2022, the Company issued 1,000,000 1,000,000 500,000 500,000 1,000,000 1,000,000 500,000 500,000 0.13 0.19 [xi] During the three months ended July 31, 2022, upon the exercise of common share purchase warrants, the Company issued an aggregate 8,131,975 0.19 1,205,077 1,545,075 800,000 0.05 31,051 40,000 17,414,239 13,725 [xii] During the three months ended July 31, 2022, upon the exercise of stock options, the Company issued an aggregate 250,000 0.13 25,340 32,500 150,000 0.12 13,853 18,000 600,000 0.05 23,272 30,000 48,060 [c] Common share purchase warrants Common share purchase warrants attached to units as part of a unit placement were assigned a $nil value. A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2022 are as follows: SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2021 Granted Exercised Expired/ Cancelled July 31, 2022 Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2021 Granted Exercised Expired/ Cancelled July 31, 2022 November 22, 2021 CA$ 0.19 – 4,160,021 – (4,080,573 ) (79,448 ) – January 17, 2022 CA$ 0.19 – 7,267,914 – (5,959,396 ) (1,308,518 ) – January 31, 2022 CA$ 0.19 – 5,382,303 – (4,341,906 ) (1,040,397 ) – February 21, 2022 CA$ 0.05 – 1,505,200 – (200,000 ) (1,305,200 ) – March 24, 2022 CA$ 0.19 – 6,341,872 – (4,515,139 ) (1,826,733 ) – March 27, 2022 CA$ 0.05 – 982,025 – (882,025 ) (100,000 ) – April 27, 2022 CA$ 0.19 – 791,395 – (791,395 ) – – May 9, 2022 CA$ 0.05 – 1,813,725 – (1,800,000 ) (13,725 ) – May 30, 2022 CA$ 0.19 – 5,223,420 – (4,070,006 ) (1,153,414 ) – June 17, 2022 CA$ 0.19 – 17,703,506 – (5,731,721 ) (11,971,785 ) – July 18, 2022 CA$ 0.30 – 4,350,000 – (60,960 ) (4,289,040 ) – August 14, 2022 CA$ 0.05 0.04 200,000 – (200,000 ) – – February 13, 2023 CA$ 0.65 0.54 3,827,601 – – – 3,827,601 April 22, 2024 CA$ 0.20 1.73 – 933,333 – – 933,333 Subtotal 59,548,982 933,333 (32,633,121 ) (23,088,260 ) 31,120,873 Weighted average exercise price CA$ 0.22 CA$ 0.20 CA$ 0.18 CA$ 0.20 CA$ 0.56 November 27, 2022 US$ 0.75 0.33 – 1,375,499 – – 1,375,499 May 9, 2023 US$ 0.45 0.77 – 1,727,000 – – 1,727,000 Jun 3, 2023 US$ 0.45 0.84 – 740,000 – – 740,000 June 10, 2026 US$ 0.13 3.86 – 4,000,000 – – 1,500,000 June 10, 2026 US$ 0.19 3.86 – 4,000,000 – – 1,500,000 Subtotal – 11,842,499 – – 11,842,499 Weighted average exercise price – US$ 0.29 – – US$ 0.29 Total 59,548,982 12,775,832 (32,633,121 ) (5,660,296 ) 38,496,372 A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2021 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2020 Granted Exercised Expired/ Cancelled July 31, 2021 August 31, 2021 * CA$ 0.21 0.08 3,643,791 – – – 3,643,791 November 22, 2021 CA$ 0.19 0.31 – 5,599,171 – – 5,599,171 January 17, 2022 CA$ 0.19 0.46 – 7,400,214 (70,000 ) (62,300 ) 7,267,914 January 31, 2022 CA$ 0.19 0.50 – 5,382,303 – – 5,382,303 February 21, 2022 CA$ 0.05 0.56 1,505,200 – – – 1,505,200 March 24, 2022 CA$ 0.19 0.65 – 6,554,172 – – 6,554,172 March 27, 2022 CA$ 0.05 0.65 1,482,025 – – – 1,482,025 April 27, 2022 CA$ 0.19 0.74 – 851,395 – – 851,395 May 9, 2022 CA$ 0.05 0.77 2,368,626 – (54,901 ) – 2,313,725 May 30, 2022 CA$ 0.19 0.82 – 5,223,420 – – 5,223,420 June 17, 2022 CA$ 0.19 0.88 – 17,853,506 – – 17,853,506 July 18, 2022 CA$ 0.30 0.96 – 4,350,000 – – 4,350,000 August 14, 2022 CA$ 0.05 1.04 1,110,000 – (400,000 ) – 710,000 Total 10,109,642 53,214,181 (524,901 ) (62,300 ) 62,736,622 Weighted average exercise price CA$ 0.11 CA$ 0.19 CA$ 0.07 CA$ 0.19 CA$ 0.19 * The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 extending the expiry date from January 17, 2021 to August 31, 2021 0.30 [d] Stock options The Company has adopted an incentive stock option plan, effective on August 8, 2017 and as amended on August 8, 2018, under the rules of the TSX-V pursuant to which it is authorized to grant stock options to executive officers, directors, employees and consultants, enabling them to acquire up to 20 Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company On June 11, 2021, the Company adopted the 2021 Equity Incentive Plan which replaces the 2017 Stock Option for providing stock-based compensation to directors, officers, employees, consultants, and advisors of the Company and no further options will be granted under the 2017 Stock Option Plan. Under the 2021 Equity Incentive Plan, the Company is authorized to issue up to 27,312,368 6,780,000 1,730,000 34,092,368 29,042,368 On December 30, 2020, the Company granted 15,650,000 0.13 9,500,000 6,150,000 On August 30, 2021, the Company granted 21,700,000 0.70 On October 1, 2021, the Company granted 1,450,000 0.50 five years On December 3, 2021, the Company granted 250,000 0.58 five years On March 7, 2022, the Company granted 500,000 0.40 five years On April 8, 2022, the Company granted 500,000 0.40 five years As at July 31, 2022, 10,042,368 During the nine months July 31, 2022, the Company recognized a stock-based compensation totaling $ 466,368 1,057,013 The weighted average grant date fair value of the stock options granted during the nine months ended July 31, 2022 was CA$ 0.37 0.09 SCHEDULE OF FAIR VALUE ASSUMPTIONS 2022 2021 Risk free rate of interest 1.34 2.59 0.20 1.07 Expected life of options 5 2 5 Exercise price of options CA$ 0.40 0.58 CA$ 0.13 0.70 Expected annualized volatility 134.93 136.08 130.88 140.05 Expected dividend rate Nil Nil A summary of the changes in the Company’s stock options during the nine months ended July 31, 2022 are as follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2021 Granted Exercised Expired/ Cancelled Outstanding as at July 31, 2022 Vested as at July 31, 2022 March 27, 2022 0.05 – 1,500,000 – (750,000 ) (750,000 ) – – December 30, 2022 0.13 0.42 6,000,000 – (250,000 ) (650,000 ) 5,100,000 5,100,000 August 12, 2023 0.05 1.03 2,290,000 – – (750,000 ) 1,540,000 1,540,000 December 3, 2023 0.05 1.34 6,450,000 – (600,000 ) (1,500,000 ) 4,350,000 4,350,000 May 22, 2024 0.12 1.81 7,900,000 – – (850,000 ) 7,050,000 7,050,000 November 3, 2024 0.15 2.26 700,000 – – – 700,000 700,000 November 24, 2024 0.16 2.32 320,000 – – (300,000 ) 20,000 20,000 March 26, 2025 0.11 2.65 100,000 – – – 100,000 100,000 April 23, 2025 0.12 2.73 3,350,000 – (150,000 ) (250,000 ) 2,950,000 2,950,000 December 30, 2025 0.13 3.42 9,500,000 – – – 9,500,000 9,500,000 August 30, 2026 0.70 4.08 21,700,000 – – (350,000 ) 21,350,000 21,312,500 October 1, 2026 0.50 4.17 1,450,000 – – – 1,450,000 1,450,000 December 3, 2026 0.58 4.35 – 250,000 – – 250,000 250,000 March 7, 2027 0.40 4.60 – 500,000 – – 500,000 500,000 April 8, 2027 0.40 4.69 – 500,000 – – 500,000 500,000 Total 61,260,000 1,250,000 (1,750,000 ) (5,400,000 ) 55,360,000 55,322,500 Weighted average exercise price CA$ 0.33 CA$ 0.44 CA$ 0.07 CA$ 0.12 CA$ 0.36 CA$ 0.36 Aggregate intrinsic value $ 19,994,025 ($ 8,475,724 ) ($ 8,459,933 ) Weighted average remaining life 3.46 2.96 2.96 A summary of the changes in the Company’s nonvested stock options during the nine months ended July 31, 2022 are as follows: SCHEDULE OF NON-VESTED STOCK OPTIONS Expiry Date Fair Value Per Share Weighted Average Life (Years) Nonvested as at October 31, 2021 Granted Vested Expired/ Cancelled Nonvested as at July 31, 2022 December 30, 2022 0.07 0.42 162,500 – (162,500 ) – – August 30, 2026 0.56 4.08 300,000 – (187,500 ) (75,000 ) 37,500 Total 462,500 – (350,000 ) (75,000 ) 37,500 Weighted average grant date fair value – per option CA$ 0.39 – CA$ 0.33 CA$ 0.56 CA$ 0.56 Weighted average grant date fair value – total $ 144,131 – $ 90,209 $ 32,652 $ 16,326 A summary of the changes in the Company’s stock options during the nine months ended July 31, 2021 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2020 Granted Exercised Expired/ Cancelled Outstanding as at July 31, 2021 Vested as at July 31, 2021 February 11, 2021 0.05 0.03 800,000 – – (800,000 ) – – August 16, 2021 0.05 0.54 600,000 – – – 600,000 600,000 March 27, 2022 0.05 1.15 1,750,000 – – – 1,750,000 1,750,000 August 26, 2022 0.13 – 500,000 – – (500,000 ) – – December 30, 2022 0.13 1.91 – 6,150,000 – – 6,150,000 5,825,000 April 19, 2023 0.05 2.21 800,000 – – – 800,000 800,000 August 12, 2023 0.05 2.53 3,120,000 – (300,000 ) – 2,820,000 2,820,000 December 3, 2023 0.05 2.84 7,000,000 – – – 7,000,000 7,000,000 May 22, 2024 0.12 3.31 7,950,000 – – – 7,950,000 7,950,000 November 3, 2024 0.15 3.76 700,000 – – – 700,000 700,000 November 24, 2024 0.16 3.82 900,000 – – – 900,000 900,000 March 26, 2025 0.11 4.15 300,000 – – – 300,000 300,000 April 23, 2025 0.12 4.23 4,000,000 – – (300,000 ) 3,700,000 3,700,000 December 30, 2025 0.13 4.92 – 9,500,000 – – 9,500,000 9,500,000 Total 28,420,000 15,650,000 (300,000 ) (1,600,000 ) 42,170,000 41,845,000 Weighted average exercise price CA$ 0.09 CA$ 0.13 CA$ 0.05 CA$ 0.09 CA$ 0.10 CA$ 0.10 Aggregate intrinsic value $ 801,922 $ 6,819,812 $ 6,774,173 Weighted average remaining life 3.18 2.80 2.81 [e] Share-based payments and other reserves The share-based payments and other reserves are used to recognize the fair value of stock options granted to directors, officers, employees and consultants as part of their remuneration, as well as those of broker warrants issued in relation to the Company’s financings. When stock options and broker warrants are subsequently exercised, the fair value of such stock options and broker warrants in additional paid-in capit0al is credited to share capital. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of its outstanding warrants and broker warrants denominated in Canadian dollar as derivative liability measured at fair value. The previous value of outstanding broker warrants was reversed out of additional paid-in capital. On November 1, 2021, the Company’s functional currency change resulted in the reclassification of the June 2021 Convertible Debenture from a hybrid financial instrument to a convertible debt instrument with a beneficial conversion feature. The value of the embedded derivative liability was reclassified to additional paid-in capital. During the nine months ended July 31, 2022, the Company also allocated the intrinsic value of the beneficial conversion feature of the April 2022 Convertible Debenture to additional paid-in capital. [f] Obligations to issue shares The Company received advance share subscriptions in respect of non-brokered private placements closed in a subsequent period. [g] Dilutive common shares As at July 31, 2022, potentially dilutive common shares relating to common share purchase warrants and stock options outstanding totaling 71,963,433 120,808,982 SCHEDULE OF POTENTIALLY DILUTIVE COMMON SHARES July 31, 2022 October 31, 2021 Common share purchase warrants 16,603,433 59,548,982 Stock options 55,360,000 61,260,000 Total 71,963,433 120,808,982 |
FINANCIAL INSTRUMENTS AND FINAN
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT | 9 Months Ended |
Jul. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT | 15. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT The Company’s classification of its financial instruments is as follows: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Instruments Measurement Method Associated Risk Fair Value at July 31, 2022 ($) Cash FVTPL Credit and currency 16,700 Other receivables Amortized cost Credit and currency 94,696 Deposits held by related parties Amortized cost Credit and currency 349,338 Accounts payable and accrued liabilities Amortized cost Currency 3,434,539 Due to related parties Amortized cost Currency 1,520,834 Convertible debenture, net Amortized cost and FVTPL Currency 1,942,838 Warrants liability FVTPL Currency 57,080 [a] Fair value The fair value of financial instruments is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willing parties who are under no compulsion to act. The fair value of current financial instruments except derivative liability approximates their carrying values as long as they are short-term in nature or bear interest at market rates. [b] Fair value hierarchy Financial instruments that are held at fair value are categorized based on a valuation hierarchy which is determined by the valuation methodology utilized. The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1 Level 2 Level 3 The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked-to-market at the conversion date and then that fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified on the consolidated balance sheets as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. The inputs used in determining the fair value of the embedded derivative are disclosed in note 12[e] [c] Financial risk management The Company’s board of directors has the overall responsibility for the establishment and oversight of the Company’s risk management framework. The Company’s risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and in response to the Company’s activities. Management regularly monitors compliance with the Company’s risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. In the normal course of operations, the Company is exposed to various risks such as interest rate, foreign exchange, commodity, credit, and liquidity. To manage these risks, management determines what activities must be undertaken to minimize potential exposure to risks. The objectives of the Company in managing risks are as follows: ● Maintaining sound financial condition; ● Financing operations; and ● Ensuring liquidity to all operations. In order to satisfy these objectives, the Company has adopted the following policies: ● Recognize and observe the extent of operating risk within the business; and ● Identify the magnitude of the impact of market risk factors on the overall risk of the business and take advantage of natural risk reductions that arise from these relationships. [i] Interest rate risk Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in the market interest rates. The Company is exposed to interest rate risk on its cash on deposits with banks and, from time to time, on its holdings of short-term investments. As of July 31, 2022, the Company had $ 16,700 462,360 no [ii] Foreign currency risk The Company is exposed to foreign currency risk on fluctuations related to cash, other receivables, accounts payable, due to related parties and convertible debenture that are denominated in Canadian dollar. The Company has not entered into foreign exchange derivative contracts. A significant change in the currency exchange rates between the US dollar relative to the Canadian dollar could have a material effect on the Company’s financial position, results of operations, or cash flows. Based on the Company net exposures as at July 31, 2022, assuming that all other variables remain constant, a 5 124,237 The Company had the following assets and liabilities denominated in Canadian dollar: SCHEDULE OF FOREIGN CURRENCY RISK July 31, 2022 CA$ Cash 4,757 Other receivables 123,701 Accounts payable and accrued liabilities (2,309,520 ) Due to related parties (1,005,314 ) Total (3,186,376 ) [iii] Commodity price risk The value of the Company’s magnesium production business and its exploration and evaluation assets are dependent on the price of magnesium and the outlook for this mineral. Market prices for these metals historically have fluctuated widely and are affected by numerous factors outside the Company’s control, including but not limited to, levels of worldwide production, short-term changes in supply and demand, industrial and retail demand, as well as certain other factors related specifically to magnesium. If magnesium prices decline for a prolonged period below the cost of production, it may not be economically feasible to continue towards production. [iv] Credit risk Credit risk is the risk of loss if counterparties do not fulfill their contractual obligations. The Company’s credit risk is primarily attributable to cash and deposits held by related parties. The Company limits its exposure to credit risk on cash as these financial instruments are held with major Canadian and international banks. Deposits held by related parties were in relation to vendor agreements entered on January 1, 2021 where the Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses [note 8[a]] [v] Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company’s exposure to liquidity risk is dependent on its purchasing commitments and obligations and its ability to raise funds to meet commitments and sustain operations. The Company manages liquidity risk by continuously monitoring its actual and forecasted working capital requirements to ensure there is capital to meet short-term and long-term obligations. As of July 31, 2022 and October 31, 2021, the Company had working capital deficiency of $ 6,642,252 9,657,316 note 1 |
SEGMENTED INFORMATION
SEGMENTED INFORMATION | 9 Months Ended |
Jul. 31, 2022 | |
Segment Reporting [Abstract] | |
SEGMENTED INFORMATION | 16. SEGMENTED INFORMATION The Company focuses on plant operations and magnesium production and continues to move towards the buildout of its pilot plant facility and the development of a full-scale commercial magnesium production facility. The Company also owns mining claims for the exploration and development of mineral property interests. Geographic information for the Company’s assets is as follows: SCHEDULE OF ASSETS INFORMATION July 31, 2022 October 31, 2021 $ $ Canada – property, plant and equipment 4,458,609 2,546,383 United States – property, plant and equipment 29,392 28,321 United States – mineral property costs 93,453 93,453 Property, plant and equipment net 4,581,454 2,668,157 Canada – other assets 311,300 1,554,827 United States – other assets 905,009 290,528 Other assets 1,216,309 1,845,355 Total Assets 5,797,763 4,513,512 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Jul. 31, 2022 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | 17. SUBSEQUENT EVENTS On August 5, 2022, the Company granted 1,000,000 0.16 two years On August 5, 2022, the Board of Directors of the Company accepted the resignation of a director. The size of the board is effectively reduced from six to five directors. On August 17, 2022, the Company issued 1,000,000 1,000,000 500,000 0.13 500,000 0.19 On August 26, 2022, the Board of Directors of the Company accepted the termination of its independent registered public accounting firm (the “Firm”). During the Firm’s tenure, there were no disagreements on any matter of accounting principles or practices, financial statement disclosure, or auditing scope of procedure which disagreement if not resolved to the satisfaction of the Firm would have caused it to make reference to the subject matter of the disagreement in connection with its reports on the financial statements, and there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K). On August 29, 2022, the Chief Financial Officer’s contract with the Company was terminated and a new interim Chief Financial Officer was appointed effective September 8, 2022. |
PROPERTY, PLANT AND EQUIPMENT (
PROPERTY, PLANT AND EQUIPMENT (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT | SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Computer Equipment Furniture Leasehold Improvement Furnace & Plant Equipment Vehicle Total $ $ $ $ $ $ Cost Balance, October 31, 2021 109,629 53,542 139,481 2,344,726 – 2,647,378 Property, plant and equipment cost, beginning balance 109,629 53,542 139,481 2,344,726 – 2,647,378 Additions 14,370 2,171 159,065 2,047,779 29,215 2,252,600 Foreign exchange effect 10 (314 ) (5,708 ) (76,255 ) (374 ) (82,641 ) Balance, July 31, 2022 124,009 55,399 292,838 4,316,250 28,841 4,817,337 Property, plant and equipment cost, ending balance 124,009 55,399 292,838 4,316,250 28,841 4,817,337 Accumulated Depreciation Balance, October 31, 2021 27,821 16,514 14,147 14,192 – 72,674 Property, plant and equipment accumulated depreciation, beginning balance 27,821 16,514 14,147 14,192 – 72,674 Depreciation expense 28,402 5,777 81,553 137,294 5,084 258,515 Foreign exchange effect 403 (52 ) (856 ) (906 ) (37 ) (1,853 ) Balance, July 31, 2022 56,626 22,239 94,844 150,580 5,047 329,336 Property, plant and equipment accumulated depreciation, ending balance 56,626 22,239 94,844 150,580 5,047 329,336 Net Book Value Balance, October 31, 2021 81,808 37,028 125,334 2,330,534 – 2,574,704 Balance, July 31, 2022 67,383 33,160 197,994 4,165,670 23,794 4,488,001 |
RIGHT-OF-USE ASSETS (Tables)
RIGHT-OF-USE ASSETS (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Right-of-use Assets | |
SCHEDULE OF RIGHT-OF-USE ASSETS | SCHEDULE OF RIGHT-OF-USE ASSETS Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Cost Balance, October 31, 2021 156,881 292,391 24,580 384,946 858,798 Beginning balance, Cost 156,881 292,391 24,580 384,946 858,798 Foreign exchange effect – (3,038 ) – (13,208 ) (16,246 ) Balance, July 31, 2022 156,881 289,353 24,580 371,738 842,552 Ending balance, Cost 156,881 289,353 24,580 371,738 842,552 Accumulated Depreciation Balance, October 31, 2021 90,277 15,529 24,580 129,837 260,223 Beginning balance, Accumulated Depreciation 90,277 15,529 24,580 129,837 260,223 Depreciation expense 33,456 50,562 – 93,720 177,738 Prepaid expense – 4,557 – – 4,557 Foreign exchange effect – (162 ) – (5,125 ) (5,287 ) Balance, July 31, 2022 123,733 70,486 24,580 218,432 437,231 Ending balance, Accumulated Depreciation 123,733 70,486 24,580 218,432 437,231 Net Book Value Balance, October 31, 2021 66,604 276,862 – 255,109 598,575 Balance, July 31, 2022 33,148 218,867 – 153,306 405,321 |
LEASE OBLIGATIONS (Tables)
LEASE OBLIGATIONS (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Lease Obligations | |
SCHEDULE OF OPERATING LEASE | SCHEDULE OF OPERATING LEASE Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 Lease obligation, beginning 66,604 262,612 – 255,109 584,325 Lease payments (36,087 ) (4,557 ) – (103,028 ) (143,672 ) Interest expense 2,631 13,967 – 9,307 25,905 Foreign exchange effect – (2,728 ) – (8,081 ) (10,089 ) Balance, July 31, 2022 33,148 269,294 – 153,307 455,749 Lease obligation, ending 33,148 269,294 – 153,307 455,749 Which consist of: Current lease obligation 33,148 96,043 – 130,745 259,936 Non-current lease obligation – 173,251 – 22,562 195,813 Balance, July 31, 2022 33,148 269,294 – 153,307 455,749 Lease obligation, ending 33,148 269,294 – 153,307 455,749 |
RELATED PARTY TRANSACTIONS (Tab
RELATED PARTY TRANSACTIONS (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Related Party Transactions [Abstract] | |
SCHEDULE OF DEPOSITS HELD BY RELATED PARTY | SCHEDULE OF DEPOSITS HELD BY RELATED PARTY Related Party A [i] Related Party B [ii] Total $ $ $ Balance, October 31, 2021 291,481 194,981 486,462 Beginning balance 291,481 194,981 486,462 Advances 354,459 1,225,118 1,579,577 Costs and expenses (312,820 ) (1,420,829 ) (1,733,649 ) Foreign exchange effect 16,218 730 16,948 Balance, July 31, 2022 349,338 – 349,338 Ending balance 349,338 – 349,338 [i] Related Party A is a company controlled by a director and officer. [ii] Related Party B is a company controlled by an officer. |
SCHEDULE OF DUE TO RELATED PARTIES | SCHEDULE OF DUE TO RELATED PARTIES July 31, 2022 October 31, 2021 $ $ Wages payable to directors and officers 505,544 357,500 Benefits payable to directors and officers 725,261 539,209 Fees and expenses payable to directors and officers 290,029 127,878 Interest due to a shareholder – 2,230 Total 1,520,834 1,026,817 |
CONVERTIBLE DEBENTURE (Tables)
CONVERTIBLE DEBENTURE (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Debt Disclosure [Abstract] | |
SCHEDULE OF DERIVATIVE INSTRUMENTS | SCHEDULE OF DERIVATIVE INSTRUMENTS July 2020 Convertible Debenture July 2021 Convertible Debenture June 2021 Convertible Debenture April 2022 Convertible Debenture Total $ $ $ $ $ Debt Host Liability Balance, October 31, 2020 96,318 – – – 96,318 Fair value of debt host liability recognized – – 1 – 1 Accretion and interest expense 23,587 63 43 – 23,693 Conversion (125,560 ) – – – (125,560 ) Foreign currency translation 5,655 – – – 5,655 Balance, October 31, 2021 – 63 44 – 107 Effects of functional currency change – – 1,500,000 – 1,500,000 Fair value at inception – – – 2,000,000 2,000,000 Accretion and interest expense – 28,050 49,406 118,659 196,115 Conversion – (28,031 ) (800,000 ) – (828,031 ) Foreign currency translation – (82 ) – – (82 ) Balance, July 31, 2022 – – 749,450 2,118,659 2,868,109 Embedded Derivative Liability Balance, October 31, 2020 20,123 – – – 20,123 Fair value of embedded derivative liability recognized – – 1,646,600 – 1,646,600 Fair value adjustment (16,058 ) – 5,717,328 – 5,701,270 Conversion (5,247 ) – – – (5,247 ) Foreign currency translation 1,182 – 85,772 – 86,954 Balance, October 31, 2021 – – 7,449,700 – 7,449,700 Effects of functional currency change – 421,094 (7,449,700 ) – (7,028,606 ) Fair value adjustment – (259,447 ) – – (259,447 ) Conversion – (158,169 ) – – (158,169 ) Foreign currency translation – (3,478 ) – – (3,478 ) Balance, July 31, 2022 – – – – – Debt Discount Balance, October 31, 2021 – – – – – Effects of functional currency change – – (1,500,000 ) – (1,500,000 ) Fair value at inception – – – (240,000 ) (240,000 ) Amortization – – 814,717 12 814,729 Balance, July 31, 2022 – – (685,283 ) (239,988 ) (925,271 ) Combined Value of Convertible Debenture Balance, October 31, 2020 116,441 – – – 116,441 Balance, October 31, 2021 – 63 7,449,744 7,449,744 7,449,807 Balance, July 31, 2022 – – 64,167 1,878,671 1,942,838 |
SCHEDULE OF OPTION PRICING MODEL | The inputs used in the Black-Scholes Option Pricing Model are as follows: SCHEDULE OF OPTION PRICING MODEL April 22, November 1, October 31, June 15, July 27, 2022 2021 2021 2021 2020 Risk free rate of interest 2.65% 1.07% 1.08% 0.31% 0.26% Expected life in years 0.23 0.70 1.11 1.50 0.74 Conversion exercise price CA$ 0.12 CA$ 0.12 $ 0.10 $ 0.10 CA$ 0.15 Underlying share price of the Company CA$ 0.36 CA$ 0.75 $ 0.59 $ 0.19 CA$ 0.13 Expected volatility 99.90% 124.34% 107.62% 87.17% 82.54% Expected dividend rate Nil Nil Nil Nil Nil |
WARRANT LIABILITY (Tables)
WARRANT LIABILITY (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Warrant Liability | |
SCHEDULE OF WARRANTS LIABILITY | SCHEDULE OF WARRANTS LIABILITY Warrants Broker Warrants Total $ $ $ Warrant Liability Balance, October 31, 2021 – – – Effects of functional currency change 26,956,177 76,811 27,032,988 Fair value at inception 67,155 – 67,155 Exercised (5,036,522 ) (20,590 ) (5,057,112 ) Fair value adjustment (21,929,730 ) (56,221 ) (21,985,951 ) Balance, July 31, 2022 57,080 – 57,080 Change in Fair Value of Warrant Liability Effects of functional currency change (26,956,177 ) (76,811 ) (27,032,988 ) Additional paid-in capital adjustment – 4,198 4,198 Fair value at inception (67,155 ) – (67,155 ) Cashless warrant exercised (113,765 ) – (113,765 ) Fair value adjustment 21,929,730 56,221 21,985,951 Total (5,207,367 ) (16,392 ) (5,223,759 ) |
SHARE CAPITAL (Tables)
SHARE CAPITAL (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Equity [Abstract] | |
SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS | A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2022 are as follows: SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2021 Granted Exercised Expired/ Cancelled July 31, 2022 Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2021 Granted Exercised Expired/ Cancelled July 31, 2022 November 22, 2021 CA$ 0.19 – 4,160,021 – (4,080,573 ) (79,448 ) – January 17, 2022 CA$ 0.19 – 7,267,914 – (5,959,396 ) (1,308,518 ) – January 31, 2022 CA$ 0.19 – 5,382,303 – (4,341,906 ) (1,040,397 ) – February 21, 2022 CA$ 0.05 – 1,505,200 – (200,000 ) (1,305,200 ) – March 24, 2022 CA$ 0.19 – 6,341,872 – (4,515,139 ) (1,826,733 ) – March 27, 2022 CA$ 0.05 – 982,025 – (882,025 ) (100,000 ) – April 27, 2022 CA$ 0.19 – 791,395 – (791,395 ) – – May 9, 2022 CA$ 0.05 – 1,813,725 – (1,800,000 ) (13,725 ) – May 30, 2022 CA$ 0.19 – 5,223,420 – (4,070,006 ) (1,153,414 ) – June 17, 2022 CA$ 0.19 – 17,703,506 – (5,731,721 ) (11,971,785 ) – July 18, 2022 CA$ 0.30 – 4,350,000 – (60,960 ) (4,289,040 ) – August 14, 2022 CA$ 0.05 0.04 200,000 – (200,000 ) – – February 13, 2023 CA$ 0.65 0.54 3,827,601 – – – 3,827,601 April 22, 2024 CA$ 0.20 1.73 – 933,333 – – 933,333 Subtotal 59,548,982 933,333 (32,633,121 ) (23,088,260 ) 31,120,873 Weighted average exercise price CA$ 0.22 CA$ 0.20 CA$ 0.18 CA$ 0.20 CA$ 0.56 November 27, 2022 US$ 0.75 0.33 – 1,375,499 – – 1,375,499 May 9, 2023 US$ 0.45 0.77 – 1,727,000 – – 1,727,000 Jun 3, 2023 US$ 0.45 0.84 – 740,000 – – 740,000 June 10, 2026 US$ 0.13 3.86 – 4,000,000 – – 1,500,000 June 10, 2026 US$ 0.19 3.86 – 4,000,000 – – 1,500,000 Subtotal – 11,842,499 – – 11,842,499 Weighted average exercise price – US$ 0.29 – – US$ 0.29 Total 59,548,982 12,775,832 (32,633,121 ) (5,660,296 ) 38,496,372 A summary of the changes in the Company’s common share purchase warrants during the nine months ended July 31, 2021 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2020 Granted Exercised Expired/ Cancelled July 31, 2021 August 31, 2021 * CA$ 0.21 0.08 3,643,791 – – – 3,643,791 November 22, 2021 CA$ 0.19 0.31 – 5,599,171 – – 5,599,171 January 17, 2022 CA$ 0.19 0.46 – 7,400,214 (70,000 ) (62,300 ) 7,267,914 January 31, 2022 CA$ 0.19 0.50 – 5,382,303 – – 5,382,303 February 21, 2022 CA$ 0.05 0.56 1,505,200 – – – 1,505,200 March 24, 2022 CA$ 0.19 0.65 – 6,554,172 – – 6,554,172 March 27, 2022 CA$ 0.05 0.65 1,482,025 – – – 1,482,025 April 27, 2022 CA$ 0.19 0.74 – 851,395 – – 851,395 May 9, 2022 CA$ 0.05 0.77 2,368,626 – (54,901 ) – 2,313,725 May 30, 2022 CA$ 0.19 0.82 – 5,223,420 – – 5,223,420 June 17, 2022 CA$ 0.19 0.88 – 17,853,506 – – 17,853,506 July 18, 2022 CA$ 0.30 0.96 – 4,350,000 – – 4,350,000 August 14, 2022 CA$ 0.05 1.04 1,110,000 – (400,000 ) – 710,000 Total 10,109,642 53,214,181 (524,901 ) (62,300 ) 62,736,622 Weighted average exercise price CA$ 0.11 CA$ 0.19 CA$ 0.07 CA$ 0.19 CA$ 0.19 * The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 extending the expiry date from January 17, 2021 to August 31, 2021 0.30 |
SCHEDULE OF FAIR VALUE ASSUMPTIONS | SCHEDULE OF FAIR VALUE ASSUMPTIONS 2022 2021 Risk free rate of interest 1.34 2.59 0.20 1.07 Expected life of options 5 2 5 Exercise price of options CA$ 0.40 0.58 CA$ 0.13 0.70 Expected annualized volatility 134.93 136.08 130.88 140.05 Expected dividend rate Nil Nil |
SCHEDULE OF STOCK OPTIONS ACTIVITY | A summary of the changes in the Company’s stock options during the nine months ended July 31, 2022 are as follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2021 Granted Exercised Expired/ Cancelled Outstanding as at July 31, 2022 Vested as at July 31, 2022 March 27, 2022 0.05 – 1,500,000 – (750,000 ) (750,000 ) – – December 30, 2022 0.13 0.42 6,000,000 – (250,000 ) (650,000 ) 5,100,000 5,100,000 August 12, 2023 0.05 1.03 2,290,000 – – (750,000 ) 1,540,000 1,540,000 December 3, 2023 0.05 1.34 6,450,000 – (600,000 ) (1,500,000 ) 4,350,000 4,350,000 May 22, 2024 0.12 1.81 7,900,000 – – (850,000 ) 7,050,000 7,050,000 November 3, 2024 0.15 2.26 700,000 – – – 700,000 700,000 November 24, 2024 0.16 2.32 320,000 – – (300,000 ) 20,000 20,000 March 26, 2025 0.11 2.65 100,000 – – – 100,000 100,000 April 23, 2025 0.12 2.73 3,350,000 – (150,000 ) (250,000 ) 2,950,000 2,950,000 December 30, 2025 0.13 3.42 9,500,000 – – – 9,500,000 9,500,000 August 30, 2026 0.70 4.08 21,700,000 – – (350,000 ) 21,350,000 21,312,500 October 1, 2026 0.50 4.17 1,450,000 – – – 1,450,000 1,450,000 December 3, 2026 0.58 4.35 – 250,000 – – 250,000 250,000 March 7, 2027 0.40 4.60 – 500,000 – – 500,000 500,000 April 8, 2027 0.40 4.69 – 500,000 – – 500,000 500,000 Total 61,260,000 1,250,000 (1,750,000 ) (5,400,000 ) 55,360,000 55,322,500 Weighted average exercise price CA$ 0.33 CA$ 0.44 CA$ 0.07 CA$ 0.12 CA$ 0.36 CA$ 0.36 Aggregate intrinsic value $ 19,994,025 ($ 8,475,724 ) ($ 8,459,933 ) Weighted average remaining life 3.46 2.96 2.96 A summary of the changes in the Company’s stock options during the nine months ended July 31, 2021 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2020 Granted Exercised Expired/ Cancelled Outstanding as at July 31, 2021 Vested as at July 31, 2021 February 11, 2021 0.05 0.03 800,000 – – (800,000 ) – – August 16, 2021 0.05 0.54 600,000 – – – 600,000 600,000 March 27, 2022 0.05 1.15 1,750,000 – – – 1,750,000 1,750,000 August 26, 2022 0.13 – 500,000 – – (500,000 ) – – December 30, 2022 0.13 1.91 – 6,150,000 – – 6,150,000 5,825,000 April 19, 2023 0.05 2.21 800,000 – – – 800,000 800,000 August 12, 2023 0.05 2.53 3,120,000 – (300,000 ) – 2,820,000 2,820,000 December 3, 2023 0.05 2.84 7,000,000 – – – 7,000,000 7,000,000 May 22, 2024 0.12 3.31 7,950,000 – – – 7,950,000 7,950,000 November 3, 2024 0.15 3.76 700,000 – – – 700,000 700,000 November 24, 2024 0.16 3.82 900,000 – – – 900,000 900,000 March 26, 2025 0.11 4.15 300,000 – – – 300,000 300,000 April 23, 2025 0.12 4.23 4,000,000 – – (300,000 ) 3,700,000 3,700,000 December 30, 2025 0.13 4.92 – 9,500,000 – – 9,500,000 9,500,000 Total 28,420,000 15,650,000 (300,000 ) (1,600,000 ) 42,170,000 41,845,000 Weighted average exercise price CA$ 0.09 CA$ 0.13 CA$ 0.05 CA$ 0.09 CA$ 0.10 CA$ 0.10 Aggregate intrinsic value $ 801,922 $ 6,819,812 $ 6,774,173 Weighted average remaining life 3.18 2.80 2.81 |
SCHEDULE OF NON-VESTED STOCK OPTIONS | A summary of the changes in the Company’s nonvested stock options during the nine months ended July 31, 2022 are as follows: SCHEDULE OF NON-VESTED STOCK OPTIONS Expiry Date Fair Value Per Share Weighted Average Life (Years) Nonvested as at October 31, 2021 Granted Vested Expired/ Cancelled Nonvested as at July 31, 2022 December 30, 2022 0.07 0.42 162,500 – (162,500 ) – – August 30, 2026 0.56 4.08 300,000 – (187,500 ) (75,000 ) 37,500 Total 462,500 – (350,000 ) (75,000 ) 37,500 Weighted average grant date fair value – per option CA$ 0.39 – CA$ 0.33 CA$ 0.56 CA$ 0.56 Weighted average grant date fair value – total $ 144,131 – $ 90,209 $ 32,652 $ 16,326 |
SCHEDULE OF POTENTIALLY DILUTIVE COMMON SHARES | SCHEDULE OF POTENTIALLY DILUTIVE COMMON SHARES July 31, 2022 October 31, 2021 Common share purchase warrants 16,603,433 59,548,982 Stock options 55,360,000 61,260,000 Total 71,963,433 120,808,982 |
FINANCIAL INSTRUMENTS AND FIN_2
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS | The Company’s classification of its financial instruments is as follows: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Instruments Measurement Method Associated Risk Fair Value at July 31, 2022 ($) Cash FVTPL Credit and currency 16,700 Other receivables Amortized cost Credit and currency 94,696 Deposits held by related parties Amortized cost Credit and currency 349,338 Accounts payable and accrued liabilities Amortized cost Currency 3,434,539 Due to related parties Amortized cost Currency 1,520,834 Convertible debenture, net Amortized cost and FVTPL Currency 1,942,838 Warrants liability FVTPL Currency 57,080 |
SCHEDULE OF FOREIGN CURRENCY RISK | The Company had the following assets and liabilities denominated in Canadian dollar: SCHEDULE OF FOREIGN CURRENCY RISK July 31, 2022 CA$ Cash 4,757 Other receivables 123,701 Accounts payable and accrued liabilities (2,309,520 ) Due to related parties (1,005,314 ) Total (3,186,376 ) |
SEGMENTED INFORMATION (Tables)
SEGMENTED INFORMATION (Tables) | 9 Months Ended |
Jul. 31, 2022 | |
Segment Reporting [Abstract] | |
SCHEDULE OF ASSETS INFORMATION | SCHEDULE OF ASSETS INFORMATION July 31, 2022 October 31, 2021 $ $ Canada – property, plant and equipment 4,458,609 2,546,383 United States – property, plant and equipment 29,392 28,321 United States – mineral property costs 93,453 93,453 Property, plant and equipment net 4,581,454 2,668,157 Canada – other assets 311,300 1,554,827 United States – other assets 905,009 290,528 Other assets 1,216,309 1,845,355 Total Assets 5,797,763 4,513,512 |
NATURE OF OPERATIONS AND GOIN_2
NATURE OF OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($) | 9 Months Ended | ||
Jul. 31, 2022 | Jul. 31, 2021 | Oct. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Accumulated deficit | $ 67,190,772 | $ 52,129,621 | |
Working capital deficit | 6,642,252 | $ 9,657,316 | |
Comprehensive income (loss) | 14,829,915 | $ 6,513,804 | |
Cash | $ 6,000,000 |
SCHEDULE OF PROPERTY, PLANT AND
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) | 9 Months Ended | ||
Jul. 31, 2022 | Jul. 31, 2021 | Oct. 31, 2021 | |
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment cost, beginning balance | $ 2,647,378 | ||
Additions | 2,252,600 | ||
Foreign exchange effect | (82,641) | ||
Property, plant and equipment cost, ending balance | 4,817,337 | ||
Property, plant and equipment accumulated depreciation, beginning balance | 72,674 | ||
Depreciation expense | 258,515 | $ 22,355 | |
Foreign exchange effect | (1,853) | ||
Property, plant and equipment accumulated depreciation, ending balance | 329,336 | ||
Property, plant and equipment net book value | 4,488,001 | $ 2,574,704 | |
Computer Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment cost, beginning balance | 109,629 | ||
Additions | 14,370 | ||
Foreign exchange effect | 10 | ||
Property, plant and equipment cost, ending balance | 124,009 | ||
Property, plant and equipment accumulated depreciation, beginning balance | 27,821 | ||
Depreciation expense | 28,402 | ||
Foreign exchange effect | 403 | ||
Property, plant and equipment accumulated depreciation, ending balance | 56,626 | ||
Property, plant and equipment net book value | 67,383 | 81,808 | |
Furniture and Fixtures [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment cost, beginning balance | 53,542 | ||
Additions | 2,171 | ||
Foreign exchange effect | (314) | ||
Property, plant and equipment cost, ending balance | 55,399 | ||
Property, plant and equipment accumulated depreciation, beginning balance | 16,514 | ||
Depreciation expense | 5,777 | ||
Foreign exchange effect | (52) | ||
Property, plant and equipment accumulated depreciation, ending balance | 22,239 | ||
Property, plant and equipment net book value | 33,160 | 37,028 | |
Leasehold Improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment cost, beginning balance | 139,481 | ||
Additions | 159,065 | ||
Foreign exchange effect | (5,708) | ||
Property, plant and equipment cost, ending balance | 292,838 | ||
Property, plant and equipment accumulated depreciation, beginning balance | 14,147 | ||
Depreciation expense | 81,553 | ||
Foreign exchange effect | (856) | ||
Property, plant and equipment accumulated depreciation, ending balance | 94,844 | ||
Property, plant and equipment net book value | 197,994 | 125,334 | |
Furnace and Plant Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment cost, beginning balance | 2,344,726 | ||
Additions | 2,047,779 | ||
Foreign exchange effect | (76,255) | ||
Property, plant and equipment cost, ending balance | 4,316,250 | ||
Property, plant and equipment accumulated depreciation, beginning balance | 14,192 | ||
Depreciation expense | 137,294 | ||
Foreign exchange effect | (906) | ||
Property, plant and equipment accumulated depreciation, ending balance | 150,580 | ||
Property, plant and equipment net book value | 4,165,670 | 2,330,534 | |
Vehicles [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment cost, beginning balance | |||
Additions | 29,215 | ||
Foreign exchange effect | (374) | ||
Property, plant and equipment cost, ending balance | 28,841 | ||
Property, plant and equipment accumulated depreciation, beginning balance | |||
Depreciation expense | 5,084 | ||
Foreign exchange effect | (37) | ||
Property, plant and equipment accumulated depreciation, ending balance | 5,047 | ||
Property, plant and equipment net book value | $ 23,794 |
SCHEDULE OF RIGHT-OF-USE ASSETS
SCHEDULE OF RIGHT-OF-USE ASSETS (Details) - USD ($) | 9 Months Ended | ||
Jul. 31, 2022 | Jul. 31, 2021 | Oct. 31, 2021 | |
Beginning balance, Cost | $ 858,798 | ||
Foreign exchange effect | (16,246) | ||
Ending balance, Cost | 842,552 | ||
Beginning balance, Accumulated Depreciation | 260,223 | ||
Depreciation expense | 177,738 | $ 137,419 | |
Prepaid expense | 4,557 | ||
Foreign exchange effect | (5,287) | ||
Ending balance, Accumulated Depreciation | 437,231 | ||
Net book value | 405,321 | $ 598,575 | |
Vancouver Office [Member] | |||
Beginning balance, Cost | 156,881 | ||
Foreign exchange effect | |||
Ending balance, Cost | 156,881 | ||
Beginning balance, Accumulated Depreciation | 90,277 | ||
Depreciation expense | 33,456 | ||
Prepaid expense | |||
Foreign exchange effect | |||
Ending balance, Accumulated Depreciation | 123,733 | ||
Net book value | 33,148 | 66,604 | |
Virginia Office [Member] | |||
Beginning balance, Cost | 292,391 | ||
Foreign exchange effect | (3,038) | ||
Ending balance, Cost | 289,353 | ||
Beginning balance, Accumulated Depreciation | 15,529 | ||
Depreciation expense | 50,562 | ||
Prepaid expense | 4,557 | ||
Foreign exchange effect | (162) | ||
Ending balance, Accumulated Depreciation | 70,486 | ||
Net book value | 218,867 | 276,862 | |
Nevada Office [Member] | |||
Beginning balance, Cost | 24,580 | ||
Foreign exchange effect | |||
Ending balance, Cost | 24,580 | ||
Beginning balance, Accumulated Depreciation | 24,580 | ||
Depreciation expense | |||
Prepaid expense | |||
Foreign exchange effect | |||
Ending balance, Accumulated Depreciation | 24,580 | ||
Net book value | |||
Pilot Plant [Member] | |||
Beginning balance, Cost | 384,946 | ||
Foreign exchange effect | (13,208) | ||
Ending balance, Cost | 371,738 | ||
Beginning balance, Accumulated Depreciation | 129,837 | ||
Depreciation expense | 93,720 | ||
Prepaid expense | |||
Foreign exchange effect | (5,125) | ||
Ending balance, Accumulated Depreciation | 218,432 | ||
Net book value | $ 153,306 | $ 255,109 |
SCHEDULE OF OPERATING LEASE (De
SCHEDULE OF OPERATING LEASE (Details) - USD ($) | 9 Months Ended | |
Jul. 31, 2022 | Oct. 31, 2021 | |
Lease obligation, beginning | $ 584,325 | |
Lease payments | (143,672) | |
Interest expense | 25,905 | |
Foreign exchange effect | (10,089) | |
Lease obligation, ending | 455,749 | |
Current lease obligation | 259,936 | $ 192,045 |
Non-current lease obligation | 195,813 | $ 392,280 |
Vancouver Office [Member] | ||
Lease obligation, beginning | 66,604 | |
Lease payments | (36,087) | |
Interest expense | 2,631 | |
Foreign exchange effect | ||
Lease obligation, ending | 33,148 | |
Current lease obligation | 33,148 | |
Non-current lease obligation | ||
Virginia Office [Member] | ||
Lease obligation, beginning | 262,612 | |
Lease payments | (4,557) | |
Interest expense | 13,967 | |
Foreign exchange effect | (2,728) | |
Lease obligation, ending | 269,294 | |
Current lease obligation | 96,043 | |
Non-current lease obligation | 173,251 | |
Nevada Office [Member] | ||
Lease obligation, beginning | ||
Lease payments | ||
Interest expense | ||
Foreign exchange effect | ||
Lease obligation, ending | ||
Current lease obligation | ||
Non-current lease obligation | ||
Pilot Plant [Member] | ||
Lease obligation, beginning | 255,109 | |
Lease payments | (103,028) | |
Interest expense | 9,307 | |
Foreign exchange effect | (8,081) | |
Lease obligation, ending | 153,307 | |
Current lease obligation | 130,745 | |
Non-current lease obligation | $ 22,562 |
LEASE OBLIGATIONS (Details Narr
LEASE OBLIGATIONS (Details Narrative) - USD ($) | Jul. 31, 2022 | Oct. 31, 2021 | Oct. 31, 2020 | Nov. 02, 2019 |
Operating lease, liability | $ 455,749 | $ 584,325 | $ 83,549 | |
Lessee, operating lease, discount rate | 7% | |||
British Columbia [Member] | ||||
Operating lease, liability | $ 91,237 | $ 354,263 | ||
Lessee, operating lease, discount rate | 7% | 6% | ||
McLean,Virginia [Member] | ||||
Operating lease, liability | $ 260,649 | |||
Lessee, operating lease, discount rate | 7% |
MINERAL PROPERTY COSTS (Details
MINERAL PROPERTY COSTS (Details Narrative) | Jul. 31, 2022 USD ($) a ha | Oct. 31, 2021 USD ($) |
Reserve Quantities [Line Items] | ||
Mineral properties, net | $ 93,453 | $ 93,453 |
Silverado Property [Member] | ||
Reserve Quantities [Line Items] | ||
Area of land | ha | 120 | |
Ownership percentage | 100% | |
Carrying value of property | $ 1 | |
TamiMosi Property [Member] | ||
Reserve Quantities [Line Items] | ||
Ownership percentage | 100% | |
Royalty percentage | 2% | |
Mineral properties, net | $ 93,452 | |
TamiMosi Property [Member] | White Pine County [Member] | ||
Reserve Quantities [Line Items] | ||
Area of land | a | 1,637 | |
TamiMosi Property [Member] | Moor Mining District [Member] | ||
Reserve Quantities [Line Items] | ||
Area of land | a | 10 |
SCHEDULE OF DEPOSITS HELD BY RE
SCHEDULE OF DEPOSITS HELD BY RELATED PARTY (Details) | 9 Months Ended | |
Jul. 31, 2022 USD ($) | ||
Related Party Transaction [Line Items] | ||
Beginning balance | $ 486,462 | |
Advances | 1,579,577 | |
Costs and expenses | (1,733,649) | |
Foreign exchange effect | 16,948 | |
Ending balance | 349,338 | |
Related Party A [Member] | ||
Related Party Transaction [Line Items] | ||
Beginning balance | 291,481 | [1] |
Advances | 354,459 | [1] |
Costs and expenses | (312,820) | [1] |
Foreign exchange effect | 16,218 | [1] |
Ending balance | 349,338 | [1] |
Related Party B [Member] | ||
Related Party Transaction [Line Items] | ||
Beginning balance | 194,981 | [2] |
Advances | 1,225,118 | [2] |
Costs and expenses | (1,420,829) | [2] |
Foreign exchange effect | 730 | [2] |
Ending balance | [2] | |
[1]Related Party A is a company controlled by a director and officer.[2]Related Party B is a company controlled by an officer. |
SCHEDULE OF DUE TO RELATED PART
SCHEDULE OF DUE TO RELATED PARTIES (Details) - USD ($) | Jul. 31, 2022 | Oct. 31, 2021 |
Related Party Transactions [Abstract] | ||
Wages payable to directors and officers | $ 505,544 | $ 357,500 |
Benefits payable to directors and officers | 725,261 | 539,209 |
Fees and expenses payable to directors and officers | 290,029 | 127,878 |
Interest due to a shareholder | 2,230 | |
Total | $ 1,520,834 | $ 1,026,817 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) | 1 Months Ended | 9 Months Ended | ||||||||
Nov. 03, 2021 USD ($) shares | Nov. 03, 2021 CAD ($) $ / shares shares | Sep. 12, 2018 | Aug. 28, 2018 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 CAD ($) | Jul. 31, 2022 USD ($) | Jul. 31, 2022 CAD ($) | Jul. 31, 2021 USD ($) | Oct. 31, 2021 USD ($) | |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Due to related parties | $ 1,520,834 | $ 1,026,817 | ||||||||
Stock based compensation | 3,300,000 | |||||||||
Number of common stock issued, value | 774,746 | $ 5,157,833 | ||||||||
Directors and Officers [Member] | ||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Salaries management and consulting fees | 2,605,352 | |||||||||
Directors and Officers [Member] | Sublease Agreement [Member] | ||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Lease description | lease term from April 1, 2021 to March 31, 2023 | lease term from April 1, 2021 to March 31, 2023 | ||||||||
Payments for rent | $ 7,637 | $ 9,794 | ||||||||
Directors and Officers [Member] | Sublease Agreement [Member] | Vancouver, British Columbia [Member] | ||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Lease description | lease term from April 1, 2021 to March 31, 2023 | lease term from April 1, 2021 to March 31, 2023 | ||||||||
Payments for rent | $ 7,656 | $ 9,794 | ||||||||
Officer [Member] | ||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Stock based compensation | 160,700 | |||||||||
Management [Member] | ||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Consulting fees | 27,489 | $ 35,000 | ||||||||
Executive Officer [Member] | ||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Consulting fees | 60,000 | |||||||||
Executive [Member] | ||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Consulting fees | $ 29,600 | |||||||||
Director and Officer [Member] | Related Party Agreement [Member] | ||||||||||
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] | ||||||||||
Equity method investment, ownership percentage | 5% | |||||||||
Number of common stock issued, value | $ 4,796,832 | $ 5,956,226 | $ 5,000,000 | |||||||
Number of common stock issued, shares | shares | 9,163,425 | 9,163,425 | ||||||||
Share price | $ / shares | $ 0.65 |
CONTINGENT LIABILITIES AND CO_2
CONTINGENT LIABILITIES AND COMMITMENTS (Details Narrative) | 1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||||||
Mar. 04, 2022 USD ($) | Feb. 08, 2021 USD ($) shares | Feb. 08, 2021 CAD ($) shares | Dec. 31, 2020 USD ($) | Dec. 31, 2020 CAD ($) | Sep. 29, 2020 USD ($) | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 CAD ($) | Jul. 31, 2022 USD ($) shares | Jul. 31, 2022 CAD ($) shares | Jul. 31, 2021 USD ($) shares | Oct. 31, 2020 USD ($) | Oct. 31, 2020 CAD ($) | Apr. 22, 2022 CAD ($) | Nov. 03, 2021 $ / shares | Oct. 31, 2021 USD ($) | Apr. 19, 2021 USD ($) | Nov. 01, 2016 USD ($) | Nov. 01, 2016 CAD ($) $ / shares | |
Loss Contingencies [Line Items] | ||||||||||||||||||||
Loss contingency, damages sought, value | $ 3,900,000 | $ 4,900,000 | $ 3,400,000 | $ 4,200,000 | ||||||||||||||||
Debt instrument, face amount | $ 100,000 | |||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.65 | |||||||||||||||||||
Cash | $ 6,000,000 | |||||||||||||||||||
Tenant allowance | 41,010 | |||||||||||||||||||
Lodestar Management Group LLC [Member] | ||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||
Debt instrument, face amount | 38,593 | $ 53,491 | ||||||||||||||||||
Commitment of cash or arrangments amount | $ 1,800 | $ 2,500 | ||||||||||||||||||
Number of shares issued price per share | $ / shares | $ 0.05 | |||||||||||||||||||
Issuance of share based minimum requirement | $ 1,800 | $ 2,500 | ||||||||||||||||||
Number of shares issued | shares | 0 | 0 | ||||||||||||||||||
Cash | $ 30,624 | $ 16,200 | ||||||||||||||||||
Number of shares outstanding | shares | 634,072 | |||||||||||||||||||
Lampert Agreement [Member] | ||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||
Debt instrument, face amount | $ 367,227 | |||||||||||||||||||
Debt instrument, interest rate | 9% | |||||||||||||||||||
Lease Agreement [Member] | ||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||
Loss contingency, damages sought, value | $ 120,000 | |||||||||||||||||||
Lease term description | lease term from September 14, 2021 to February 28, 2025 | lease term from October 1, 2020 to September 30, 2023 | lease term from October 1, 2020 to September 30, 2023 | |||||||||||||||||
Payments for rent | $ 9,113 | $ 16,154 | $ 20,715 | |||||||||||||||||
Sublease Agreement [Member] | Directors and Officers [Member] | ||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||
Lease term description | lease term from April 1, 2021 to March 31, 2023 | lease term from April 1, 2021 to March 31, 2023 | ||||||||||||||||||
Payments for rent | $ 7,637 | $ 9,794 | ||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||
Loss Contingencies [Line Items] | ||||||||||||||||||||
Loss contingency, damages sought, value | $ 2,500,000 | |||||||||||||||||||
Warrant to purchase common stock | shares | 33,000,000 | 33,000,000 |
PROMISSORY NOTE (Details Narrat
PROMISSORY NOTE (Details Narrative) | 9 Months Ended | 12 Months Ended | ||||||
Jul. 31, 2022 USD ($) | Jul. 31, 2021 USD ($) | Oct. 31, 2021 USD ($) | Oct. 31, 2020 USD ($) | Oct. 31, 2020 CAD ($) | Oct. 31, 2019 USD ($) | Oct. 31, 2019 CAD ($) | Oct. 31, 2020 CAD ($) | |
Short-Term Debt [Line Items] | ||||||||
Proceeds from related party loan | $ 1,579,577 | |||||||
Repayments of debt | $ 65,745 | |||||||
Promissory Note [Member] | ||||||||
Short-Term Debt [Line Items] | ||||||||
Proceeds from related party loan | $ 112,895 | $ 150,000 | ||||||
Percentage of unsecured loan interest | 18% | 18% | ||||||
Additional increase in promissory note loan | $ 44,588 | $ 60,000 | ||||||
Loans payable | $ 157,483 | $ 210,000 | ||||||
Maturity date | Sep. 24, 2021 | Sep. 24, 2021 | ||||||
Interest and debt expense | $ 1,639 | $ 16,655 | ||||||
Repayments of debt | $ 65,761 | $ 101,066 |
PROVISION FOR FLOW THROUGH SH_2
PROVISION FOR FLOW THROUGH SHARE ISSUANCES (Details Narrative) - USD ($) | Jul. 31, 2022 | Oct. 31, 2021 |
Provision For Flow Through Share Issuances | ||
Provision for tax and related obligations | $ 225,284 | $ 233,285 |
SCHEDULE OF DERIVATIVE INSTRUME
SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Jul. 31, 2022 | Jul. 31, 2021 | Jul. 31, 2022 | Jul. 31, 2021 | Oct. 31, 2021 | |
Short-Term Debt [Line Items] | |||||
Accretion and interest expense | $ 372,295 | $ 28,242 | $ 1,021,443 | $ 64,576 | |
Foreign currency translation | 17,273 | 16,068 | 231,236 | (174,981) | |
Fair value adjustment | $ (806,853) | 359,643 | (790,197) | ||
Amortization | 814,729 | ||||
Debt Host Liability [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 107 | 96,318 | $ 96,318 | ||
Fair value of debt host liability recognized | 1 | ||||
Accretion and interest expense | 196,115 | 23,693 | |||
Conversion | (828,031) | (125,560) | |||
Foreign currency translation | (82) | 5,655 | |||
Effects of functional currency change | 1,500,000 | ||||
Fair value at inception | 2,000,000 | ||||
Balance, ending | 2,868,109 | 2,868,109 | 107 | ||
Debt Host Liability [Member] | July 2020 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 96,318 | 96,318 | |||
Fair value of debt host liability recognized | |||||
Accretion and interest expense | 23,587 | ||||
Conversion | (125,560) | ||||
Foreign currency translation | 5,655 | ||||
Effects of functional currency change | |||||
Fair value at inception | |||||
Balance, ending | |||||
Debt Host Liability [Member] | July 2021 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 63 | ||||
Fair value of debt host liability recognized | |||||
Accretion and interest expense | 28,050 | 63 | |||
Conversion | (28,031) | ||||
Foreign currency translation | (82) | ||||
Effects of functional currency change | |||||
Fair value at inception | |||||
Balance, ending | 63 | ||||
Debt Host Liability [Member] | June 2021 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 44 | ||||
Fair value of debt host liability recognized | 1 | ||||
Accretion and interest expense | 49,406 | 43 | |||
Conversion | (800,000) | ||||
Foreign currency translation | |||||
Effects of functional currency change | 1,500,000 | ||||
Fair value at inception | |||||
Balance, ending | 749,450 | 749,450 | 44 | ||
Debt Host Liability [Member] | April 2022 Convertible debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | |||||
Fair value of debt host liability recognized | |||||
Accretion and interest expense | 118,659 | ||||
Conversion | |||||
Foreign currency translation | |||||
Effects of functional currency change | |||||
Fair value at inception | 2,000,000 | ||||
Balance, ending | 2,118,659 | 2,118,659 | |||
Embedded Derivative Liability [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 7,449,700 | 20,123 | 20,123 | ||
Conversion | (158,169) | (5,247) | |||
Foreign currency translation | (3,478) | 86,954 | |||
Effects of functional currency change | (7,028,606) | ||||
Balance, ending | 7,449,700 | ||||
Fair value of embedded derivative liability recognized | 1,646,600 | ||||
Fair value adjustment | (259,447) | 5,701,270 | |||
Embedded Derivative Liability [Member] | July 2020 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 20,123 | 20,123 | |||
Conversion | (5,247) | ||||
Foreign currency translation | 1,182 | ||||
Effects of functional currency change | |||||
Balance, ending | |||||
Fair value of embedded derivative liability recognized | |||||
Fair value adjustment | (16,058) | ||||
Embedded Derivative Liability [Member] | July 2021 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | |||||
Conversion | (158,169) | ||||
Foreign currency translation | (3,478) | ||||
Effects of functional currency change | 421,094 | ||||
Balance, ending | |||||
Fair value of embedded derivative liability recognized | |||||
Fair value adjustment | (259,447) | ||||
Embedded Derivative Liability [Member] | June 2021 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 7,449,700 | ||||
Conversion | |||||
Foreign currency translation | 85,772 | ||||
Effects of functional currency change | (7,449,700) | ||||
Balance, ending | 7,449,700 | ||||
Fair value of embedded derivative liability recognized | 1,646,600 | ||||
Fair value adjustment | 5,717,328 | ||||
Embedded Derivative Liability [Member] | April 2022 Convertible debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | |||||
Conversion | |||||
Foreign currency translation | |||||
Effects of functional currency change | |||||
Balance, ending | |||||
Fair value of embedded derivative liability recognized | |||||
Fair value adjustment | |||||
Debt Discount [Member] | |||||
Short-Term Debt [Line Items] | |||||
Effects of functional currency change | (1,500,000) | ||||
Fair value at inception | (240,000) | ||||
Balance, beginning | |||||
Amortization | 814,729 | ||||
Balance, ending | (925,271) | (925,271) | |||
Debt Discount [Member] | July 2020 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Effects of functional currency change | |||||
Fair value at inception | |||||
Balance, beginning | |||||
Amortization | |||||
Balance, ending | |||||
Debt Discount [Member] | July 2021 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Effects of functional currency change | |||||
Fair value at inception | |||||
Balance, beginning | |||||
Amortization | |||||
Balance, ending | |||||
Debt Discount [Member] | June 2021 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Effects of functional currency change | (1,500,000) | ||||
Fair value at inception | |||||
Balance, beginning | |||||
Amortization | 814,717 | ||||
Balance, ending | (685,283) | (685,283) | |||
Debt Discount [Member] | April 2022 Convertible debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Effects of functional currency change | |||||
Fair value at inception | (240,000) | ||||
Balance, beginning | |||||
Amortization | 12 | ||||
Balance, ending | (239,988) | (239,988) | |||
Combined Value of Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 7,449,807 | 116,441 | 116,441 | ||
Balance, ending | 1,942,838 | 1,942,838 | 7,449,807 | ||
Combined Value of Convertible Debenture [Member] | July 2020 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 116,441 | 116,441 | |||
Balance, ending | |||||
Combined Value of Convertible Debenture [Member] | July 2021 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 63 | ||||
Balance, ending | 63 | ||||
Combined Value of Convertible Debenture [Member] | June 2021 Convertible Debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 7,449,744 | ||||
Balance, ending | 64,167 | 64,167 | 7,449,744 | ||
Combined Value of Convertible Debenture [Member] | April 2022 Convertible debenture [Member] | |||||
Short-Term Debt [Line Items] | |||||
Balance, beginning | 7,449,744 | ||||
Balance, ending | $ 1,878,671 | $ 1,878,671 | $ 7,449,744 |
SCHEDULE OF OPTION PRICING MODE
SCHEDULE OF OPTION PRICING MODEL (Details) | 9 Months Ended | ||
Jul. 31, 2022 $ / shares | Jul. 31, 2021 | Jul. 31, 2022 $ / shares | |
Short-Term Debt [Line Items] | |||
Expected life in years | 5 years | ||
Expected dividend rate | |||
April 22, 2022 [Member] | |||
Short-Term Debt [Line Items] | |||
Risk free rate of interest | 2.65% | ||
Expected life in years | 2 months 23 days | ||
Conversion exercise price | $ 0.12 | ||
Underlying share price of the Company | 0.36 | ||
Expected volatility | 99.90% | ||
Expected dividend rate | |||
November 1, 2021 [Member] | |||
Short-Term Debt [Line Items] | |||
Risk free rate of interest | 1.07% | ||
Expected life in years | 8 months 12 days | ||
Conversion exercise price | 0.12 | ||
Underlying share price of the Company | 0.75 | ||
Expected volatility | 124.34% | ||
Expected dividend rate | |||
October 31, 2021 [Member] | |||
Short-Term Debt [Line Items] | |||
Risk free rate of interest | 1.08% | ||
Expected life in years | 1 year 1 month 9 days | ||
Conversion exercise price | $ 0.10 | ||
Underlying share price of the Company | $ 0.59 | ||
Expected volatility | 107.62% | ||
Expected dividend rate | |||
June 15, 2021 [Member] | |||
Short-Term Debt [Line Items] | |||
Risk free rate of interest | 0.31% | ||
Expected life in years | 1 year 6 months | ||
Conversion exercise price | $ 0.10 | ||
Underlying share price of the Company | $ 0.19 | ||
Expected volatility | 87.17% | ||
Expected dividend rate | |||
July 27, 2020 [Member] | |||
Short-Term Debt [Line Items] | |||
Risk free rate of interest | 0.26% | ||
Expected life in years | 8 months 26 days | ||
Conversion exercise price | 0.15 | ||
Underlying share price of the Company | $ 0.13 | ||
Expected volatility | 82.54% | ||
Expected dividend rate |
CONVERTIBLE DEBENTURE (Details
CONVERTIBLE DEBENTURE (Details Narrative) | 9 Months Ended | 12 Months Ended | |||||||||||||
Jun. 08, 2022 shares | Apr. 22, 2022 CAD ($) $ / shares shares | Apr. 14, 2022 USD ($) $ / shares shares | Jun. 15, 2021 USD ($) shares | May 18, 2021 USD ($) shares | Jul. 31, 2022 USD ($) $ / shares shares | Jul. 31, 2022 CAD ($) shares | Jul. 31, 2021 USD ($) shares | Oct. 31, 2021 USD ($) | Jul. 31, 2022 CAD ($) shares | Nov. 03, 2021 $ / shares | Jul. 15, 2021 USD ($) | Jul. 15, 2021 CAD ($) $ / shares | Jul. 27, 2020 USD ($) | Jul. 27, 2020 CAD ($) $ / shares | |
Short-Term Debt [Line Items] | |||||||||||||||
Debt instrument, face amount | $ 100,000 | ||||||||||||||
Common stock, value issued | $ 41,811,321 | $ 29,842,167 | |||||||||||||
Warrants exercisable price | $ / shares | $ 0.20 | ||||||||||||||
Penalty cash | 6,000,000 | ||||||||||||||
Beneficial conversion feature was reversed out of additional paid-in capital | 240,000 | ||||||||||||||
Debt host liability share, face value | $ / shares | $ 0.65 | ||||||||||||||
Amortization of debt discount premium | $ 814,729 | ||||||||||||||
Common Stock [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Number of shares issued | shares | 3,842,499 | 3,842,499 | 53,151,881 | ||||||||||||
Beneficial conversion feature was reversed out of additional paid-in capital | |||||||||||||||
July 2020 Convertible Debenture [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Debt instrument, face amount | $ 112,124 | $ 150,000 | |||||||||||||
Debt instrument, interest rate percentage | 12% | 12% | |||||||||||||
Debt instrument, conversion price | $ / shares | $ 0.15 | ||||||||||||||
Number of shares issued | shares | 1,360,959 | ||||||||||||||
Conversion of stock, shares issued | shares | 263,973 | ||||||||||||||
Common stock, value issued | $ 26,286 | ||||||||||||||
Effective interest rate percentage | 37% | ||||||||||||||
Debt instrument, fair value | 87,083 | ||||||||||||||
Embedded derivative liability | 25,041 | ||||||||||||||
July 2021 Convertible Debenture [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Debt instrument, face amount | $ 79,542 | $ 100,000 | |||||||||||||
Debt instrument, interest rate percentage | 12% | 12% | |||||||||||||
Debt instrument, conversion price | $ / shares | $ 0.12 | ||||||||||||||
Conversion of stock, shares issued | shares | 933,333 | ||||||||||||||
Effective interest rate percentage | 594% | ||||||||||||||
Warrants exercisable price | $ / shares | $ 0.20 | ||||||||||||||
Convertible debenture face value | 79,542 | $ 100,000 | |||||||||||||
Embedded derivative liability | 421,095 | $ 529,400 | |||||||||||||
Beneficial conversion feature was reversed out of additional paid-in capital | $ 341,553 | $ 429,400 | |||||||||||||
June 2021 Convertible Debenture [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Debt instrument, face amount | $ 1,500,000 | ||||||||||||||
Debt instrument, interest rate percentage | 12% | ||||||||||||||
Number of shares issued | shares | 1,000,000 | 8,000,000 | 8,000,000 | ||||||||||||
Debt instrument maturity date | Dec. 10, 2022 | ||||||||||||||
Conversion of convertiable debenture | shares | 15,000,000 | ||||||||||||||
Debt conversion, description | each unit consists of (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion | each unit consists of (i) one share of the Company’ common stock, (ii) one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion | |||||||||||||
Contractual interest | $ 165,140 | 70,521 | |||||||||||||
Debt instrument interest rate description | effective interest rate of 1,113% | effective interest rate of 1,113% | |||||||||||||
Debt instrument, fair value | $ 1,500,000 | ||||||||||||||
Embedded derivative liability | $ 1,646,600 | ||||||||||||||
Debt host liability share, face value | $ / shares | $ 1 | ||||||||||||||
Loss on recognition of debt liability | $ 146,601 | ||||||||||||||
Convertible debt combined value | 7,449,744 | ||||||||||||||
Amortization of debt discount premium | 814,717 | ||||||||||||||
Debt discount carry value | $ 685,283 | ||||||||||||||
June 2021 Convertible Debenture [Member] | Common Class A [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | ||||||||||||||
Number of warrants exercisable | shares | 500,000 | 4,000,000 | 4,000,000 | ||||||||||||
June 2021 Convertible Debenture [Member] | Common Class B [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | ||||||||||||||
Number of warrants exercisable | shares | 500,000 | 4,000,000 | 4,000,000 | ||||||||||||
June 2021 Convertible Debenture [Member] | Common Stock [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Number of shares issued | shares | 1,000,000 | 8,000,000 | 8,000,000 | ||||||||||||
April 2022 Convertible debenture [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Debt instrument, face amount | $ 2,000,000 | ||||||||||||||
Debt instrument, interest rate percentage | 15% | ||||||||||||||
Effective interest rate percentage | 22% | 22% | |||||||||||||
Debt instrument maturity date | Oct. 14, 2023 | ||||||||||||||
Contractual interest | $ 88,767 | ||||||||||||||
Penalty cash | $ 20,000 | ||||||||||||||
Convertible debenture face value | 240,000 | ||||||||||||||
Debt discount carry value | 239,988 | ||||||||||||||
Interest expense | $ 12 | ||||||||||||||
April 2022 Convertible debenture [Member] | Common Stock [Member] | |||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||
Number of shares issued | shares | 6,666,667 | ||||||||||||||
Warrants exercisable price | $ / shares | $ 0.40 | ||||||||||||||
Warrants term | 5 years |
SCHEDULE OF WARRANTS LIABILITY
SCHEDULE OF WARRANTS LIABILITY (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jul. 31, 2022 | Jul. 31, 2021 | Jul. 31, 2022 | Jul. 31, 2021 | |
Class of Warrant or Right [Line Items] | ||||
Balance at beginning | ||||
Fair value adjustment | $ (806,853) | 359,643 | $ (790,197) | |
Balance at end | 57,080 | 57,080 | ||
Additional paid-in capital adjustment | (4,198) | |||
Total | (1,837,031) | 5,223,759 | ||
Warrants [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Fair value adjustment | 67,155 | |||
Warrant Liability [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Balance at beginning | ||||
Effects of functional currency change | 27,032,988 | |||
Fair value at inception | 67,155 | |||
Exercised | (5,057,112) | |||
Fair value adjustment | (21,985,951) | |||
Balance at end | 57,080 | 57,080 | ||
Warrant Liability [Member] | Warrants [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Balance at beginning | ||||
Effects of functional currency change | 26,956,177 | |||
Fair value at inception | 67,155 | |||
Exercised | (5,036,522) | |||
Fair value adjustment | (21,929,730) | |||
Balance at end | 57,080 | 57,080 | ||
Warrant Liability [Member] | Broker Warrants [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Balance at beginning | ||||
Effects of functional currency change | 76,811 | |||
Fair value at inception | ||||
Exercised | (20,590) | |||
Fair value adjustment | (56,221) | |||
Balance at end | ||||
Change in Fair Value of Warrant Liability [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Fair value adjustment | 21,985,951 | |||
Effects of functional currency change | (27,032,988) | |||
Additional paid-in capital adjustment | 4,198 | |||
Fair value at inception | (67,155) | |||
Cashless warrant exercised | (113,765) | |||
Total | (5,223,759) | |||
Change in Fair Value of Warrant Liability [Member] | Warrants [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Fair value adjustment | 21,929,730 | |||
Effects of functional currency change | (26,956,177) | |||
Additional paid-in capital adjustment | ||||
Fair value at inception | (67,155) | |||
Cashless warrant exercised | (113,765) | |||
Total | (5,207,367) | |||
Change in Fair Value of Warrant Liability [Member] | Broker Warrants [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Fair value adjustment | 56,221 | |||
Effects of functional currency change | (76,811) | |||
Additional paid-in capital adjustment | 4,198 | |||
Fair value at inception | ||||
Cashless warrant exercised | ||||
Total | $ (16,392) |
WARRANT LIABILITY (Details Narr
WARRANT LIABILITY (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Nov. 01, 2021 | Jul. 31, 2022 | Jul. 31, 2021 | Jul. 31, 2022 | Jul. 31, 2021 | Nov. 02, 2021 | |
Warrant outstanding | $ (4,198) | |||||
Additional derivative liability | $ (806,853) | 359,643 | $ (790,197) | |||
Brokers Warrants [Member] | ||||||
Warrant outstanding | $ 4,198 | |||||
Warrants [Member] | ||||||
Derivative Liability | 57,080 | 57,080 | $ 26,956,177 | |||
Additional derivative liability | 67,155 | |||||
Exercise of common share purchase warrants | 5,057,112 | |||||
Derivative, Loss on Derivative | 21,985,951 | |||||
Broker Warrants [Member] | ||||||
Derivative Liability | $ 76,811 |
SUMMARY OF CHANGES IN COMMON SH
SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS (Details) | 9 Months Ended | |||||
Jul. 31, 2022 $ / shares shares | Jul. 31, 2022 $ / shares $ / shares shares | Jul. 31, 2021 $ / shares shares | Jul. 31, 2022 $ / shares | Apr. 22, 2022 $ / shares | ||
Class of Warrant or Right [Line Items] | ||||||
Exercise price | $ / shares | $ 0.20 | |||||
Purchase Warrant 1 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Common share purchase warrants, Beginning balance | 59,548,982 | 59,548,982 | ||||
Granted | 933,333 | 933,333 | ||||
Exercised | (32,633,121) | (32,633,121) | ||||
Expired/Cancelled | (23,088,260) | (23,088,260) | ||||
Common share purchase warrants, Ending balance | 31,120,873 | 31,120,873 | ||||
Weighted average exercise price, beginning | $ / shares | $ 0.22 | |||||
Weighted average exercise price, granted | $ / shares | 0.20 | |||||
Weighted average exercise price, exercised | $ / shares | 0.18 | |||||
Weighted average exercise price, expired/cancelled | $ / shares | 0.20 | |||||
Weighted average exercise price, ending | $ / shares | $ 0.56 | |||||
Purchase Warrant 2 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Common share purchase warrants, Beginning balance | ||||||
Granted | 11,842,499 | 11,842,499 | ||||
Exercised | ||||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 11,842,499 | 11,842,499 | ||||
Weighted average exercise price, beginning | $ / shares | ||||||
Weighted average exercise price, granted | $ / shares | 0.29 | |||||
Weighted average exercise price, exercised | $ / shares | ||||||
Weighted average exercise price, expired/cancelled | $ / shares | ||||||
Weighted average exercise price, ending | $ / shares | $ 0.29 | |||||
Purchase Warrant [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Common share purchase warrants, Beginning balance | 59,548,982 | 59,548,982 | 10,109,642 | |||
Granted | 12,775,832 | 12,775,832 | 53,214,181 | |||
Exercised | (32,633,121) | (32,633,121) | (524,901) | |||
Expired/Cancelled | (5,660,296) | (5,660,296) | (62,300) | |||
Common share purchase warrants, Ending balance | 38,496,372 | 38,496,372 | 62,736,622 | |||
Weighted average exercise price, beginning | $ / shares | $ 0.11 | |||||
Weighted average exercise price, granted | $ / shares | 0.19 | |||||
Weighted average exercise price, exercised | $ / shares | 0.07 | |||||
Weighted average exercise price, expired/cancelled | $ / shares | 0.19 | |||||
Weighted average exercise price, ending | $ / shares | $ 0.19 | |||||
November 22, 2021 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Nov. 22, 2021 | Nov. 22, 2021 | Nov. 22, 2021 | |||
Common share purchase warrants, Beginning balance | 4,160,021 | 4,160,021 | ||||
Granted | 5,599,171 | |||||
Exercised | (4,080,573) | (4,080,573) | ||||
Expired/Cancelled | (79,448) | (79,448) | ||||
Common share purchase warrants, Ending balance | 5,599,171 | |||||
Exercise price | $ / shares | $ 0.19 | $ 0.19 | ||||
Weighted Average Life (Years) | 3 months 21 days | |||||
January 17, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Jan. 17, 2022 | Jan. 17, 2022 | Jan. 17, 2022 | |||
Common share purchase warrants, Beginning balance | 7,267,914 | 7,267,914 | ||||
Granted | 7,400,214 | |||||
Exercised | (5,959,396) | (5,959,396) | (70,000) | |||
Expired/Cancelled | (1,308,518) | (1,308,518) | (62,300) | |||
Common share purchase warrants, Ending balance | 7,267,914 | |||||
Exercise price | $ / shares | $ 0.19 | 0.19 | ||||
Weighted Average Life (Years) | 5 months 15 days | |||||
January 31, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Jan. 31, 2022 | Jan. 31, 2022 | Jan. 31, 2022 | |||
Common share purchase warrants, Beginning balance | 5,382,303 | 5,382,303 | ||||
Granted | 5,382,303 | |||||
Exercised | (4,341,906) | (4,341,906) | ||||
Expired/Cancelled | (1,040,397) | (1,040,397) | ||||
Common share purchase warrants, Ending balance | 5,382,303 | |||||
Exercise price | $ / shares | $ 0.19 | 0.19 | ||||
Weighted Average Life (Years) | 6 months | |||||
February 21, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Feb. 21, 2022 | Feb. 21, 2022 | Feb. 21, 2022 | |||
Common share purchase warrants, Beginning balance | 1,505,200 | 1,505,200 | 1,505,200 | |||
Granted | ||||||
Exercised | (200,000) | (200,000) | ||||
Expired/Cancelled | (1,305,200) | (1,305,200) | ||||
Common share purchase warrants, Ending balance | 1,505,200 | |||||
Exercise price | $ / shares | $ 0.05 | 0.05 | ||||
Weighted Average Life (Years) | 6 months 21 days | |||||
March 24, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Mar. 24, 2022 | Mar. 24, 2022 | Mar. 24, 2022 | |||
Common share purchase warrants, Beginning balance | 6,341,872 | 6,341,872 | ||||
Granted | 6,554,172 | |||||
Exercised | (4,515,139) | (4,515,139) | ||||
Expired/Cancelled | (1,826,733) | (1,826,733) | ||||
Common share purchase warrants, Ending balance | 6,554,172 | |||||
Exercise price | $ / shares | $ 0.19 | 0.19 | ||||
Weighted Average Life (Years) | 7 months 24 days | |||||
March 27, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Mar. 27, 2022 | Mar. 27, 2022 | Mar. 27, 2022 | |||
Common share purchase warrants, Beginning balance | 982,025 | 982,025 | 1,482,025 | |||
Granted | ||||||
Exercised | (882,025) | (882,025) | ||||
Expired/Cancelled | (100,000) | (100,000) | ||||
Common share purchase warrants, Ending balance | 1,482,025 | |||||
Exercise price | $ / shares | $ 0.05 | 0.05 | ||||
Weighted Average Life (Years) | 7 months 24 days | |||||
April 27, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Apr. 27, 2022 | Apr. 27, 2022 | Apr. 27, 2022 | |||
Common share purchase warrants, Beginning balance | 791,395 | 791,395 | ||||
Granted | 851,395 | |||||
Exercised | (791,395) | (791,395) | ||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 851,395 | |||||
Exercise price | $ / shares | $ 0.19 | 0.19 | ||||
Weighted Average Life (Years) | 8 months 26 days | |||||
May 9, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | May 09, 2022 | May 09, 2022 | May 09, 2022 | |||
Common share purchase warrants, Beginning balance | 1,813,725 | 1,813,725 | 2,368,626 | |||
Granted | ||||||
Exercised | (1,800,000) | (1,800,000) | (54,901) | |||
Expired/Cancelled | (13,725) | (13,725) | ||||
Common share purchase warrants, Ending balance | 2,313,725 | |||||
Exercise price | $ / shares | $ 0.05 | 0.05 | ||||
Weighted Average Life (Years) | 9 months 7 days | |||||
May 30, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | May 30, 2022 | May 30, 2022 | May 30, 2022 | |||
Common share purchase warrants, Beginning balance | 5,223,420 | 5,223,420 | ||||
Granted | 5,223,420 | |||||
Exercised | (4,070,006) | (4,070,006) | ||||
Expired/Cancelled | (1,153,414) | (1,153,414) | ||||
Common share purchase warrants, Ending balance | 5,223,420 | |||||
Exercise price | $ / shares | $ 0.19 | 0.19 | ||||
Weighted Average Life (Years) | 9 months 25 days | |||||
June 17, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Jun. 17, 2022 | Jun. 17, 2022 | Jun. 17, 2022 | |||
Common share purchase warrants, Beginning balance | 17,703,506 | 17,703,506 | ||||
Granted | 17,853,506 | |||||
Exercised | (5,731,721) | (5,731,721) | ||||
Expired/Cancelled | (11,971,785) | (11,971,785) | ||||
Common share purchase warrants, Ending balance | 17,853,506 | |||||
Exercise price | $ / shares | $ 0.19 | 0.19 | ||||
Weighted Average Life (Years) | 10 months 17 days | |||||
July 18, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Jul. 18, 2022 | Jul. 18, 2022 | Jul. 18, 2022 | |||
Common share purchase warrants, Beginning balance | 4,350,000 | 4,350,000 | ||||
Granted | 4,350,000 | |||||
Exercised | (60,960) | (60,960) | ||||
Expired/Cancelled | (4,289,040) | (4,289,040) | ||||
Common share purchase warrants, Ending balance | 4,350,000 | |||||
Exercise price | $ / shares | $ 0.30 | 0.30 | ||||
Weighted Average Life (Years) | 11 months 15 days | |||||
August 14, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Aug. 14, 2022 | Aug. 14, 2022 | Aug. 14, 2022 | |||
Common share purchase warrants, Beginning balance | 200,000 | 200,000 | 1,110,000 | |||
Granted | ||||||
Exercised | (200,000) | (200,000) | (400,000) | |||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 710,000 | |||||
Exercise price | $ / shares | $ 0.05 | $ 0.05 | ||||
Weighted Average Life (Years) | 14 days | 14 days | 1 year 14 days | 14 days | ||
February 13, 2023 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Feb. 13, 2023 | Feb. 13, 2023 | ||||
Common share purchase warrants, Beginning balance | 3,827,601 | 3,827,601 | ||||
Granted | ||||||
Exercised | ||||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 3,827,601 | 3,827,601 | ||||
Exercise price | $ / shares | $ 0.65 | |||||
Weighted Average Life (Years) | 6 months 14 days | 6 months 14 days | 6 months 14 days | |||
April 22, 2024 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Apr. 22, 2024 | Apr. 22, 2024 | ||||
Common share purchase warrants, Beginning balance | ||||||
Granted | 933,333 | 933,333 | ||||
Exercised | ||||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 933,333 | 933,333 | ||||
Exercise price | $ / shares | $ 0.20 | |||||
Weighted Average Life (Years) | 1 year 8 months 23 days | 1 year 8 months 23 days | 1 year 8 months 23 days | |||
November 27, 2022 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Nov. 27, 2022 | Nov. 27, 2022 | ||||
Common share purchase warrants, Beginning balance | ||||||
Granted | 1,375,499 | 1,375,499 | ||||
Exercised | ||||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 1,375,499 | 1,375,499 | ||||
Exercise price | $ / shares | $ 0.75 | $ 0.75 | ||||
Weighted Average Life (Years) | 3 months 29 days | 3 months 29 days | 3 months 29 days | |||
May 9, 2023 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | May 09, 2023 | May 09, 2023 | ||||
Common share purchase warrants, Beginning balance | ||||||
Granted | 1,727,000 | 1,727,000 | ||||
Exercised | ||||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 1,727,000 | 1,727,000 | ||||
Exercise price | $ / shares | $ 0.45 | $ 0.45 | ||||
Weighted Average Life (Years) | 9 months 7 days | 9 months 7 days | 9 months 7 days | |||
June 3, 2023 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Jun. 03, 2023 | Jun. 03, 2023 | ||||
Common share purchase warrants, Beginning balance | ||||||
Granted | 740,000 | 740,000 | ||||
Exercised | ||||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 740,000 | 740,000 | ||||
Exercise price | $ / shares | $ 0.45 | $ 0.45 | ||||
Weighted Average Life (Years) | 10 months 2 days | 10 months 2 days | 10 months 2 days | |||
June 10, 2026 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Jun. 10, 2026 | Jun. 10, 2026 | ||||
Common share purchase warrants, Beginning balance | ||||||
Granted | 4,000,000 | 4,000,000 | ||||
Exercised | ||||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 1,500,000 | 1,500,000 | ||||
Exercise price | $ / shares | $ 0.13 | $ 0.13 | ||||
Weighted Average Life (Years) | 3 years 10 months 9 days | 3 years 10 months 9 days | 3 years 10 months 9 days | |||
June 10, 2026 (1) [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Jun. 10, 2026 | Jun. 10, 2026 | ||||
Common share purchase warrants, Beginning balance | ||||||
Granted | 4,000,000 | 4,000,000 | ||||
Exercised | ||||||
Expired/Cancelled | ||||||
Common share purchase warrants, Ending balance | 1,500,000 | 1,500,000 | ||||
Exercise price | $ / shares | $ 0.19 | $ 0.19 | ||||
Weighted Average Life (Years) | 3 years 10 months 9 days | 3 years 10 months 9 days | 3 years 10 months 9 days | |||
August 31, 2021 [Member] | ||||||
Class of Warrant or Right [Line Items] | ||||||
Expiry Date | Aug. 31, 2021 | [1] | ||||
Common share purchase warrants, Beginning balance | 3,643,791 | [1] | ||||
Granted | [1] | |||||
Exercised | [1] | |||||
Expired/Cancelled | [1] | |||||
Common share purchase warrants, Ending balance | 3,643,791 | [1] | ||||
Exercise price | $ / shares | $ 0.21 | [1] | ||||
Weighted Average Life (Years) | 29 days | [1] | ||||
[1]The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 extending the expiry date from January 17, 2021 to August 31, 2021 0.30 |
SUMMARY OF CHANGES IN COMMON _2
SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS (Details) (Parenthetical) | Jan. 13, 2021 $ / shares shares | Jul. 31, 2022 $ / shares | Oct. 31, 2021 $ / shares |
Equity [Abstract] | |||
Class of warrant or right outstanding | 3,643,791 | ||
Warrant maturity date, description | extending the expiry date from January 17, 2021 to August 31, 2021 | ||
Common stock par or stated value per share | (per share) | $ 0.30 | $ 0.001 | $ 0.001 |
SCHEDULE OF FAIR VALUE ASSUMPTI
SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - $ / shares | 9 Months Ended | |
Jul. 31, 2022 | Jul. 31, 2021 | |
Risk free rate of interest, minimum | 1.34% | 0.20% |
Risk free rate of interest, maximum | 2.59% | 1.07% |
Expected life of options | 5 years | |
Expected annualized volatility, minimum | 134.93% | 130.88% |
Expected annualized volatility, maximum | 136.08% | 140.05% |
Expected dividend rate | ||
Minimum [Member] | ||
Expected life of options | 2 years | |
Exercise price of options | $ 0.40 | $ 0.13 |
Maximum [Member] | ||
Expected life of options | 5 years | |
Exercise price of options | $ 0.58 | $ 0.70 |
SCHEDULE OF STOCK OPTIONS ACTIV
SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) | 9 Months Ended | 12 Months Ended | ||||
Jul. 31, 2022 USD ($) shares | Jul. 31, 2022 $ / shares | Jul. 31, 2021 USD ($) shares | Jul. 31, 2021 $ / shares | Oct. 31, 2021 USD ($) shares | Oct. 31, 2021 $ / shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Total outstanding, beginning balance | 61,260,000 | 28,420,000 | 28,420,000 | |||
Total granted | 1,250,000 | 15,650,000 | ||||
Total exercised | (1,750,000) | (300,000) | ||||
Total expired/cancelled | (5,400,000) | (1,600,000) | ||||
Total outstanding, ending balance | 55,360,000 | 42,170,000 | 61,260,000 | |||
Total vested | 55,322,500 | 41,845,000 | ||||
Weighted average remaining life, outstanding | 2 years 11 months 15 days | 2 years 9 months 18 days | ||||
Weighted average exercise price, beginning balance | $ / shares | $ 0.33 | $ 0.09 | $ 0.09 | |||
Weighted average exercise price, granted | $ / shares | 0.44 | 0.13 | ||||
Weighted average exercise price, exercised | $ / shares | 0.07 | 0.05 | ||||
Weighted average exercise price, expired/cancelled | $ / shares | 0.12 | 0.09 | ||||
Weighted average exercise price, ending balance | $ / shares | 0.36 | 0.10 | $ 0.33 | |||
Weighted average exercise price, vested | $ / shares | 0.36 | 0.10 | ||||
Aggregate intrinsic value, outstanding, beginning balance | $ | $ 19,994,025 | $ 801,922 | $ 801,922 | |||
Aggregate intrinsic value, outstanding, ending balance | $ | 8,475,724 | 6,819,812 | $ 19,994,025 | |||
Aggregate intrinsic value, vested, ending balance | $ | $ 8,459,933 | $ 6,774,173 | ||||
Weighted average remaining life, outstanding | 3 years 5 months 15 days | 3 years 2 months 4 days | ||||
Weighted average remaining life, vested | 2 years 11 months 15 days | 2 years 9 months 21 days | ||||
Option One [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Mar. 27, 2022 | Feb. 11, 2021 | ||||
Share Price | $ / shares | 0.05 | 0.05 | ||||
Total outstanding, beginning balance | 1,500,000 | 800,000 | 800,000 | |||
Total granted | ||||||
Total exercised | (750,000) | |||||
Total expired/cancelled | (750,000) | (800,000) | ||||
Total outstanding, ending balance | 1,500,000 | |||||
Total vested | ||||||
Weighted average remaining life, outstanding | 10 days | |||||
Option Two [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Dec. 30, 2022 | Aug. 16, 2021 | ||||
Share Price | $ / shares | 0.13 | 0.05 | ||||
Total outstanding, beginning balance | 6,000,000 | 600,000 | 600,000 | |||
Total granted | ||||||
Total exercised | (250,000) | |||||
Total expired/cancelled | (650,000) | |||||
Total outstanding, ending balance | 5,100,000 | 600,000 | 6,000,000 | |||
Total vested | 5,100,000 | 600,000 | ||||
Weighted average remaining life, outstanding | 5 months 1 day | 6 months 14 days | ||||
Option Three [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Aug. 12, 2023 | Mar. 27, 2022 | ||||
Share Price | $ / shares | 0.05 | 0.05 | ||||
Total outstanding, beginning balance | 2,290,000 | 1,750,000 | 1,750,000 | |||
Total granted | ||||||
Total exercised | ||||||
Total expired/cancelled | (750,000) | |||||
Total outstanding, ending balance | 1,540,000 | 1,750,000 | 2,290,000 | |||
Total vested | 1,540,000 | 1,750,000 | ||||
Weighted average remaining life, outstanding | 1 year 10 days | 1 year 1 month 24 days | ||||
Option Four [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Dec. 03, 2023 | Aug. 26, 2022 | ||||
Share Price | $ / shares | 0.05 | 0.13 | ||||
Total outstanding, beginning balance | 6,450,000 | 500,000 | 500,000 | |||
Total granted | ||||||
Total exercised | (600,000) | |||||
Total expired/cancelled | (1,500,000) | (500,000) | ||||
Total outstanding, ending balance | 4,350,000 | 6,450,000 | ||||
Total vested | 4,350,000 | |||||
Weighted average remaining life, outstanding | 1 year 4 months 2 days | |||||
Option Five [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | May 22, 2024 | Dec. 30, 2022 | ||||
Share Price | $ / shares | 0.12 | 0.13 | ||||
Total outstanding, beginning balance | 7,900,000 | |||||
Total granted | 6,150,000 | |||||
Total exercised | ||||||
Total expired/cancelled | (850,000) | |||||
Total outstanding, ending balance | 7,050,000 | 6,150,000 | 7,900,000 | |||
Total vested | 7,050,000 | 5,825,000 | ||||
Weighted average remaining life, outstanding | 1 year 9 months 21 days | 1 year 10 months 28 days | ||||
Option Six [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Nov. 03, 2024 | Apr. 19, 2023 | ||||
Share Price | $ / shares | 0.15 | 0.05 | ||||
Total outstanding, beginning balance | 700,000 | 800,000 | 800,000 | |||
Total granted | ||||||
Total exercised | ||||||
Total expired/cancelled | ||||||
Total outstanding, ending balance | 700,000 | 800,000 | 700,000 | |||
Total vested | 700,000 | 800,000 | ||||
Weighted average remaining life, outstanding | 2 years 3 months 3 days | 2 years 2 months 15 days | ||||
Option Seven [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Nov. 24, 2024 | Aug. 12, 2023 | ||||
Share Price | $ / shares | 0.16 | 0.05 | ||||
Total outstanding, beginning balance | 320,000 | 3,120,000 | 3,120,000 | |||
Total granted | ||||||
Total exercised | (300,000) | |||||
Total expired/cancelled | (300,000) | |||||
Total outstanding, ending balance | 20,000 | 2,820,000 | 320,000 | |||
Total vested | 20,000 | 2,820,000 | ||||
Weighted average remaining life, outstanding | 2 years 3 months 25 days | 2 years 6 months 10 days | ||||
Option Eight [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Mar. 26, 2025 | Dec. 03, 2023 | ||||
Share Price | $ / shares | 0.11 | 0.05 | ||||
Total outstanding, beginning balance | 100,000 | 7,000,000 | 7,000,000 | |||
Total granted | ||||||
Total exercised | ||||||
Total expired/cancelled | ||||||
Total outstanding, ending balance | 100,000 | 7,000,000 | 100,000 | |||
Total vested | 100,000 | 7,000,000 | ||||
Weighted average remaining life, outstanding | 2 years 7 months 24 days | 2 years 10 months 2 days | ||||
Option Nine [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Apr. 23, 2025 | May 22, 2024 | ||||
Share Price | $ / shares | 0.12 | 0.12 | ||||
Total outstanding, beginning balance | 3,350,000 | 7,950,000 | 7,950,000 | |||
Total granted | ||||||
Total exercised | (150,000) | |||||
Total expired/cancelled | (250,000) | |||||
Total outstanding, ending balance | 2,950,000 | 7,950,000 | 3,350,000 | |||
Total vested | 2,950,000 | 7,950,000 | ||||
Weighted average remaining life, outstanding | 2 years 8 months 23 days | 3 years 3 months 21 days | ||||
Option Ten [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Dec. 30, 2025 | Nov. 03, 2024 | ||||
Share Price | $ / shares | 0.13 | 0.15 | ||||
Total outstanding, beginning balance | 9,500,000 | 700,000 | 700,000 | |||
Total granted | ||||||
Total exercised | ||||||
Total expired/cancelled | ||||||
Total outstanding, ending balance | 9,500,000 | 700,000 | 9,500,000 | |||
Total vested | 9,500,000 | 700,000 | ||||
Weighted average remaining life, outstanding | 3 years 5 months 1 day | 3 years 9 months 3 days | ||||
Option Eleven [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Aug. 30, 2026 | Nov. 24, 2024 | ||||
Share Price | $ / shares | 0.70 | 0.16 | ||||
Total outstanding, beginning balance | 21,700,000 | 900,000 | 900,000 | |||
Total granted | ||||||
Total exercised | ||||||
Total expired/cancelled | (350,000) | |||||
Total outstanding, ending balance | 21,350,000 | 900,000 | 21,700,000 | |||
Total vested | 21,312,500 | 900,000 | ||||
Weighted average remaining life, outstanding | 4 years 29 days | 3 years 9 months 25 days | ||||
Option Twelve [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Oct. 01, 2026 | Mar. 26, 2025 | ||||
Share Price | $ / shares | 0.50 | 0.11 | ||||
Total outstanding, beginning balance | 1,450,000 | 300,000 | 300,000 | |||
Total granted | ||||||
Total exercised | ||||||
Total expired/cancelled | ||||||
Total outstanding, ending balance | 1,450,000 | 300,000 | 1,450,000 | |||
Total vested | 1,450,000 | 300,000 | ||||
Weighted average remaining life, outstanding | 4 years 2 months 1 day | 4 years 1 month 24 days | ||||
Option Thirteen [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Dec. 03, 2026 | Apr. 23, 2025 | ||||
Share Price | $ / shares | 0.58 | 0.12 | ||||
Total outstanding, beginning balance | 4,000,000 | 4,000,000 | ||||
Total granted | 250,000 | |||||
Total exercised | ||||||
Total expired/cancelled | (300,000) | |||||
Total outstanding, ending balance | 250,000 | 3,700,000 | ||||
Total vested | 250,000 | 3,700,000 | ||||
Weighted average remaining life, outstanding | 4 years 4 months 6 days | 4 years 2 months 23 days | ||||
Option Fourteen [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Mar. 07, 2027 | Dec. 30, 2025 | ||||
Share Price | $ / shares | 0.40 | $ 0.13 | ||||
Total outstanding, beginning balance | ||||||
Total granted | 500,000 | 9,500,000 | ||||
Total exercised | ||||||
Total expired/cancelled | ||||||
Total outstanding, ending balance | 500,000 | 9,500,000 | ||||
Total vested | 500,000 | 9,500,000 | ||||
Weighted average remaining life, outstanding | 4 years 7 months 6 days | 4 years 11 months 1 day | ||||
Option Fifteen [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
Expiry Date | Apr. 08, 2027 | |||||
Share Price | $ / shares | $ 0.40 | |||||
Total outstanding, beginning balance | ||||||
Total granted | 500,000 | |||||
Total exercised | ||||||
Total expired/cancelled | ||||||
Total outstanding, ending balance | 500,000 | |||||
Total vested | 500,000 | |||||
Weighted average remaining life, outstanding | 4 years 8 months 8 days |
SCHEDULE OF NON-VESTED STOCK OP
SCHEDULE OF NON-VESTED STOCK OPTIONS (Details) - 9 months ended Jul. 31, 2022 | USD ($) $ / shares shares | $ / shares |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Weighted average grant date fair value per option, granted | $ / shares | ||
Nonvested, beginning balance | 462,500 | |
Nonvested, granted | ||
Nonvested, vested | (350,000) | |
Nonvested, expired, cancelled | (75,000) | |
Nonvested, ending balance | 37,500 | |
Weighted average grant date fair value per option, beginning balance | $ / shares | 0.39 | |
Weighted average grant date fair value per option, vested | $ / shares | 0.33 | |
Weighted average grant date fair value per option, expired, cancelled | $ / shares | 0.56 | |
Weighted average grant date fair value per option, ending balance | $ / shares | 0.56 | |
Weighted average grant date fair value total, beginning balance | $ | $ 144,131 | |
Weighted average grant date fair value total, granted | $ | ||
Weighted average grant date fair value total, vested | $ | $ 90,209 | |
Weighted average grant date fair value total, expired, cancelled | $ / shares | $ 32,652 | |
Weighted average grant date fair value total, ending balance | $ | $ 16,326 | |
Option One [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date | Dec. 30, 2022 | |
Weighted average grant date fair value per option, granted | $ / shares | 0.07 | |
Nonvested, beginning balance | 162,500 | |
Nonvested, granted | ||
Nonvested, vested | (162,500) | |
Nonvested, expired, cancelled | ||
Nonvested, ending balance | ||
Weighted average life (years) | 5 months 1 day | |
Option Two [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date | Aug. 30, 2026 | |
Weighted average grant date fair value per option, granted | $ / shares | $ 0.56 | |
Nonvested, beginning balance | 300,000 | |
Nonvested, granted | ||
Nonvested, vested | (187,500) | |
Nonvested, expired, cancelled | (75,000) | |
Nonvested, ending balance | 37,500 | |
Weighted average life (years) | 4 years 29 days |
SCHEDULE OF POTENTIALLY DILUTIV
SCHEDULE OF POTENTIALLY DILUTIVE COMMON SHARES (Details) - shares | 9 Months Ended | 12 Months Ended |
Jul. 31, 2022 | Oct. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 71,963,433 | 120,808,982 |
Common Share Purchase Warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 16,603,433 | 59,548,982 |
Share-Based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 55,360,000 | 61,260,000 |
SHARE CAPITAL (Details Narrativ
SHARE CAPITAL (Details Narrative) | 1 Months Ended | 3 Months Ended | 4 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jul. 31, 2022 USD ($) $ / shares shares | Jul. 13, 2022 $ / shares shares | Jun. 08, 2022 shares | Jun. 03, 2022 USD ($) shares | May 09, 2022 USD ($) shares | Apr. 18, 2022 USD ($) shares | Apr. 18, 2022 CAD ($) $ / shares shares | Apr. 08, 2022 $ / shares shares | Mar. 10, 2022 shares | Mar. 07, 2022 $ / shares shares | Jan. 20, 2022 USD ($) $ / shares shares | Dec. 13, 2021 shares | Dec. 03, 2021 $ / shares shares | Nov. 26, 2021 USD ($) $ / shares shares | Nov. 04, 2021 shares | Nov. 03, 2021 USD ($) shares | Oct. 01, 2021 $ / shares shares | Aug. 30, 2021 $ / shares shares | Aug. 11, 2021 USD ($) shares | Aug. 11, 2021 CAD ($) $ / shares shares | Jul. 16, 2021 USD ($) shares | Jul. 16, 2021 CAD ($) $ / shares shares | Jun. 17, 2021 USD ($) shares | Jun. 17, 2021 CAD ($) $ / shares shares | Jun. 07, 2021 USD ($) shares | May 28, 2021 USD ($) shares | May 28, 2021 CAD ($) $ / shares shares | May 18, 2021 USD ($) shares | May 05, 2021 CAD ($) $ / shares | Apr. 27, 2021 USD ($) shares | Apr. 27, 2021 CAD ($) $ / shares shares | Mar. 24, 2021 USD ($) shares | Mar. 24, 2021 CAD ($) $ / shares shares | Jan. 29, 2021 USD ($) shares | Jan. 29, 2021 CAD ($) $ / shares shares | Jan. 15, 2021 USD ($) shares | Jan. 15, 2021 CAD ($) shares | Dec. 30, 2020 $ / shares shares | Nov. 20, 2020 USD ($) shares | Nov. 20, 2020 CAD ($) $ / shares shares | Sep. 12, 2018 | Aug. 08, 2018 | Apr. 27, 2022 $ / shares shares | Jul. 31, 2022 USD ($) $ / shares shares | Jul. 31, 2022 CAD ($) shares | Apr. 30, 2022 USD ($) shares | Apr. 30, 2022 CAD ($) $ / shares shares | Jan. 31, 2022 USD ($) | Jan. 31, 2022 CAD ($) $ / shares shares | Jul. 31, 2021 USD ($) | Jul. 31, 2022 CAD ($) | Jul. 31, 2022 USD ($) $ / shares shares | Jul. 31, 2022 CAD ($) $ / shares shares | Jul. 31, 2021 USD ($) shares | Jul. 31, 2021 $ / shares | Oct. 31, 2021 USD ($) $ / shares shares | Oct. 31, 2021 CAD ($) shares | Jul. 31, 2022 $ / shares | Jun. 03, 2022 $ / shares | May 09, 2022 $ / shares | Apr. 22, 2022 CAD ($) $ / shares shares | Nov. 03, 2021 CAD ($) $ / shares shares | Oct. 31, 2021 $ / shares | Jun. 15, 2021 USD ($) | Jun. 11, 2021 shares | Jun. 07, 2021 CAD ($) $ / shares | Feb. 08, 2021 shares | Jan. 15, 2021 $ / shares | Jan. 13, 2021 $ / shares | Jul. 27, 2020 USD ($) | Jul. 27, 2020 CAD ($) | Aug. 29, 2018 USD ($) | |
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common voting shares | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock par value | (per share) | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.65 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, value, subscriptions | $ | $ 209,827 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets, Fair Value Disclosure | $ 4,796,832 | $ 5,956,226 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued | 449,265,776 | 9,163,425 | 449,265,776 | 449,265,776 | 392,943,398 | 933,333 | 9,163,425 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 1,250,000 | 1,250,000 | 15,650,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, value, issued | $ | $ 41,811,321 | $ 41,811,321 | $ 41,811,321 | $ 29,842,167 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 1,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | 5,943,775 | $ 4,773,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Payable | $ | $ 12,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share based compensation | $ | 32,539 | $ 1,057,013 | $ 466,368 | $ 1,057,013 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock options granted | $ / shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antidilutive securities excluded from computation of earnings per share amount | 71,963,433 | 71,963,433 | 120,808,982 | 120,808,982 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2017 Stock Option Plan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 15,650,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock option granted terms | Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2017 Stock Option Plan [Member] | Exercisable at Five Years [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options exercisable | 9,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2017 Stock Option Plan [Member] | Exercisable at Two Years [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options exercisable | 6,150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2021 Equity Incentive Plan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 10,042,368 | 500,000 | 500,000 | 250,000 | 1,450,000 | 21,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.40 | $ 0.40 | $ 0.58 | $ 0.50 | $ 0.70 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum number of common shares available | 27,312,368 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable period | 5 years | 5 years | 5 years | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class A Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | $ 0.13 | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercisable | 500,000 | 500,000 | 500,000 | 500,000 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class B Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of stock issuance costs | $ | $ 1,361 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | $ 0.19 | $ 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercisable | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Director and Officer [Member] | Related Party Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 9,163,425 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity method investment, ownership percentage | 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.65 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Option [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 750,000 | 750,000 | 2,630,000 | 2,630,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Stock Options Exercised | $ 29,715 | $ 37,500 | $ 140,734 | $ 175,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from other equity | $ | $ 48,060 | $ 22,203 | $ 121,932 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock options granted | $ / shares | $ 0.37 | $ 0.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Option [Member] | Share Price One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 250,000 | 250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 25,340 | $ 32,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Option [Member] | Share Price Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 150,000 | 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | 0.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 13,853 | $ 18,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Option [Member] | Share Price Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options granted | 600,000 | 600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Stock Options Exercised | $ 23,272 | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equipment [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,538,461 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets, Fair Value Disclosure | $ 305,832 | $ 369,231 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
July 2020 Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,360,959 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 263,973 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Issued | $ | $ 26,286 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, value, issued | $ | $ 26,286 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 112,124 | $ 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debentures [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Units | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,000,000 | 8,000,000 | 8,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 1 | $ 1 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ | $ 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Common Class A [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | $ 0.13 | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercisable | 4,000,000 | 500,000 | 4,000,000 | 4,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2021 Convertible Debenture [Member] | Common Class B [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | $ 0.19 | $ 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercisable | 4,000,000 | 500,000 | 4,000,000 | 4,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercisable | 33,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | 2017 Stock Option Plan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of authorized grant stock options | 20% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | 2021 Equity Incentive Plan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum number of common shares available | 34,092,368 | 34,092,368 | 34,092,368 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options forfeited | 29,042,368 | 29,042,368 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Director and Officers [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, value, issued | $ | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Equity Option [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | $ 0.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | 2021 Equity Incentive Plan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum number of common shares available | 6,780,000 | 6,780,000 | 6,780,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of stock options forfeited | 1,730,000 | 1,730,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Equity Option [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Options exercisable price | $ / shares | 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 3,842,499 | 3,842,499 | 53,151,881 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 8,933,333 | 8,933,333 | 1,360,959 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 2,293,946 | $ 2,899,295 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants unexercised | 15,389,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | June 2021 Convertible Debenture [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,000,000 | 8,000,000 | 8,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued | 7,014,969 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Warrant Exercises | $ 887,520 | $ 1,120,130 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock warrants expired unexercised | 525,173 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from other equity | $ | $ 4,291 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants unexercised | 2,428,363 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | 0.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercisable | 15,159,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | 2,279,136 | $ 2,880,295 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercisable | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | 7,830 | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercisable | 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 6,981 | $ 9,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Purchase Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 8,131,975 | 8,131,975 | 929,005 | 929,005 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.19 | 0.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock warrants expired unexercised | 17,414,239 | 17,414,239 | 3,191,933 | 17,414,239 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 1,205,077 | $ 1,545,075 | $ 929,005 | $ 1,177,755 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock broker warrants expired unexercised | 13,725 | 13,725 | 40,000 | 13,725 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Purchase Warrant One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 800,000 | 800,000 | 2,082,025 | 2,082,025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.05 | 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 31,051 | $ 40,000 | $ 81,354 | $ 104,101 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Purchase Warrant Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 30,960 | 30,960 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 7,357 | $ 9,288 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 3,827,601 | 3,827,601 | 4,350,000 | 4,350,000 | 25,724,955 | 25,724,955 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.25 | $ 0.55 | $ 0.20 | $ 0.13 | 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 1,683,336 | $ 2,105,180 | $ 690,860 | $ 870,000 | $ 2,621,314 | $ 3,344,244 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares description | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 for a period of eighteen months from the date of closing | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 for a period of eighteen months from the date of closing | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche | Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of stock issuance costs | $ | $ 124,923 | $ 48,319 | $ 195,614 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional stock issuance costs | $ | $ 8,444 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ | $ 3,000,000 | $ 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,727,000 | 5,223,420 | 5,223,420 | 5,599,171 | 5,599,171 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.13 | $ 0.13 | $ 0.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 431,750 | $ 561,844 | $ 679,044 | $ 556,876 | $ 727,892 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 7,337,914 | 7,337,914 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 749,435 | $ 953,930 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, value, subscriptions | $ | $ 39,996 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 5,382,303 | 5,382,303 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 547,496 | $ 699,699 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Four [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 6,554,172 | 6,554,172 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 678,270 | $ 852,042 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Five and Final [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 851,395 | 851,395 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 89,237 | $ 110,681 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Two and Final [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 740,000 | 17,853,506 | 17,853,506 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.13 | $ 0.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 185,000 | $ 1,880,687 | $ 2,320,956 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 2,467,000 | 2,467,000 | 23,076,926 | 23,076,926 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ 616,750 | $ 2,442,531 | $ 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares description | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing of the respective financing tranche | Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of $0.45 for a period of one year from the date of closing of the respective financing tranche | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of stock issuance costs | $ | $ 23,182 | $ 154,336 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Brokered Private Placement One [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares description | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche | Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | 1,375,499 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common shares price per share | $ / shares | $ 0.55 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of private placement | $ | $ 756,524 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of stock issuance costs | $ | $ 26,656 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.75 |
SCHEDULE OF CLASSIFICATION OF F
SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS (Details) | Jul. 31, 2022 USD ($) |
Fair Value Disclosures [Abstract] | |
Cash | $ 16,700 |
Other receivables | 94,696 |
Deposits held by related parties | 349,338 |
Accounts payable and accrued liabilities | 3,434,539 |
Due to related parties | 1,520,834 |
Convertible debenture, net | 1,942,838 |
Warrant liability | $ 57,080 |
SCHEDULE OF FOREIGN CURRENCY RI
SCHEDULE OF FOREIGN CURRENCY RISK (Details) | Jul. 31, 2022 CAD ($) |
Total | $ (3,186,376) |
Cash [Member] | |
Total assets | 4,757 |
Other Receivable [Member] | |
Total assets | 123,701 |
Accounts Payable and Accrued Liabilities [Member] | |
Total liabilities | (2,309,520) |
Due To Related Parties [Member] | |
Total liabilities | $ (1,005,314) |
FINANCIAL INSTRUMENTS AND FIN_3
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Details Narrative) - USD ($) | 9 Months Ended | |
Jul. 31, 2022 | Oct. 31, 2021 | |
Fair Value Disclosures [Abstract] | ||
Cash | $ 16,700 | $ 462,360 |
Short term investments | $ 0 | 0 |
Foreign currency risk rate | 5% | |
Increase decrease in foreign currency transaction amount | $ 124,237 | |
Working capital deficit | $ 6,642,252 | $ 9,657,316 |
SCHEDULE OF ASSETS INFORMATION
SCHEDULE OF ASSETS INFORMATION (Details) - USD ($) | Jul. 31, 2022 | Oct. 31, 2021 |
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
United States – property, plant and equipment | $ 4,488,001 | $ 2,574,704 |
United States – mineral property costs | 93,453 | 93,453 |
Property, plant and equipment net | 4,581,454 | 2,668,157 |
Other assets | 1,216,309 | 1,845,355 |
Total Assets | 5,797,763 | 4,513,512 |
CANADA | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
United States – property, plant and equipment | 4,458,609 | 2,546,383 |
Other assets | 311,300 | 1,554,827 |
UNITED STATES | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
United States – property, plant and equipment | 29,392 | 28,321 |
United States – mineral property costs | 93,453 | 93,453 |
Other assets | $ 905,009 | $ 290,528 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) | 9 Months Ended | |||||||||||||||||
Aug. 17, 2022 $ / shares shares | Aug. 05, 2022 $ / shares shares | Jul. 31, 2022 shares | Jun. 08, 2022 shares | Apr. 08, 2022 $ / shares shares | Mar. 07, 2022 $ / shares shares | Dec. 03, 2021 $ / shares shares | Oct. 01, 2021 $ / shares shares | Aug. 30, 2021 $ / shares shares | Jul. 31, 2022 shares | Jul. 31, 2021 shares | Jul. 13, 2022 $ / shares shares | Apr. 27, 2022 $ / shares shares | Apr. 22, 2022 $ / shares | Mar. 10, 2022 shares | Jan. 20, 2022 $ / shares shares | Dec. 13, 2021 shares | Nov. 04, 2021 shares | |
Subsequent Event [Line Items] | ||||||||||||||||||
Options granted | 1,250,000 | 15,650,000 | ||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.20 | |||||||||||||||||
Class A Warrants [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of warrants exercisable | 500,000 | 1,000,000 | 500,000 | 500,000 | 500,000 | |||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | $ 0.13 | $ 0.13 | |||||||||||||||
Class B Warrants [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of warrants exercisable | 500,000 | 1,000,000 | 500,000 | 500,000 | 500,000 | 500,000 | ||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | $ 0.19 | $ 0.19 | |||||||||||||||
Common Stock [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of shares issued | 3,842,499 | 53,151,881 | ||||||||||||||||
June 2021 Convertible Debenture [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of shares issued | 1,000,000 | 8,000,000 | ||||||||||||||||
June 2021 Convertible Debenture [Member] | Common Stock [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of shares issued | 1,000,000 | 8,000,000 | ||||||||||||||||
2021 Equity Incentive Plan [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Options granted | 10,042,368 | 500,000 | 500,000 | 250,000 | 1,450,000 | 21,700,000 | ||||||||||||
Options exercisable price | $ / shares | $ 0.40 | $ 0.40 | $ 0.58 | $ 0.50 | $ 0.70 | |||||||||||||
Options exercisable period | 5 years | 5 years | 5 years | 5 years | ||||||||||||||
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of shares issued | 1,000,000 | |||||||||||||||||
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | Class A Warrants [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of warrants exercisable | 500,000 | |||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.13 | |||||||||||||||||
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | Class B Warrants [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of warrants exercisable | 500,000 | |||||||||||||||||
Warrants exercisable price | $ / shares | $ 0.19 | |||||||||||||||||
Subsequent Event [Member] | June 2021 Convertible Debenture [Member] | Common Stock [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Number of shares issued | 1,000,000 | |||||||||||||||||
Subsequent Event [Member] | 2021 Equity Incentive Plan [Member] | Non-Statutory Stock Options [Member] | ||||||||||||||||||
Subsequent Event [Line Items] | ||||||||||||||||||
Options granted | 1,000,000 | |||||||||||||||||
Options exercisable price | $ / shares | $ 0.16 | |||||||||||||||||
Options exercisable period | 2 years |